name1,name2,name3,name4,name5,mean_cp,mean_odds,uniq_a,uniq_b,shared,score,treeLevel
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.74e-10,44.08,8,33,0,9.94,1.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,44.63,8,16,0,12.0,9.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.54e-11,44.43,8,71,0,8.9,5.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.54e-11,58.27,8,35,0,9.83,21.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.54e-11,44.36,8,110,0,8.58,21.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.37e-09,43.69,8,37,0,9.73,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.61e-06,45.62,6,9,0,10.0,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.88e-08,44.68,6,194,0,6.19,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.92e-08,43.4,6,17,0,8.12,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.88e-08,44.67,6,29,0,7.24,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.9e-08,46.85,6,14,0,8.57,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.08e-06,42.66,6,12,0,9.0,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.88e-08,41.48,6,48,0,6.75,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.88e-08,44.87,6,29,0,7.24,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.88e-08,41.92,6,98,0,6.37,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.12e-08,40.58,6,24,0,7.5,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.95e-07,46.99,6,10,0,9.6,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),3.1e-08,39.35,6,37,0,6.97,7.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.56e-08,41.15,6,20,0,7.8,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.88e-08,42.81,6,94,0,6.38,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.36e-06,48.6,6,8,0,10.5,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),1.88e-08,45.47,6,19,0,7.89,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.88e-08,42.63,6,21,0,7.71,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.16e-08,47.81,6,12,0,9.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.15e-08,55.52,6,10,0,9.6,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.01e-07,48.11,6,10,0,9.6,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.89e-08,42.43,6,21,0,7.71,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.88e-08,44.04,6,21,0,7.71,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.88e-08,42.16,6,32,0,7.12,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),5.41e-08,49.52,6,10,0,9.6,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.88e-08,48.49,6,39,0,6.92,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.88e-08,52.47,6,44,0,6.82,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.88e-08,45.34,6,113,0,6.32,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.77e-06,42.87,6,11,0,9.27,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.19e-06,42.59,6,11,0,9.27,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.78e-07,43.06,6,12,0,9.0,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.9e-08,40.95,6,25,0,7.44,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.88e-08,46.62,6,87,0,6.41,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.88e-08,41.61,6,33,0,7.09,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.88e-08,44.35,6,41,0,6.88,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.88e-08,44.52,6,21,0,7.71,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.89e-08,42.18,6,21,0,7.71,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.88e-08,43.13,6,1021,0,6.04,8.0
ghrelin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",8.92e-10,46.07,14,79,0,16.48,1.0
ghrelin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.42e-06,46.02,14,29,0,20.76,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,29.86,35,18,0,27.26,1.0
Fatty Acids (bacs),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.64e-08,23.23,7,5,0,8.57,3.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,154.0,7,9,0,12.44,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.9e-13,153.06,7,194,0,7.25,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,151.78,7,17,0,9.88,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.9e-13,153.05,7,29,0,8.69,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2e-10,155.23,7,14,0,10.5,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,151.04,7,12,0,11.08,5.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.9e-13,149.86,7,48,0,8.02,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.9e-13,153.25,7,29,0,8.69,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.9e-13,150.3,7,98,0,7.5,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,148.96,7,24,0,9.04,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,155.38,7,10,0,11.9,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,147.73,7,37,0,8.32,7.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,149.54,7,20,0,9.45,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.9e-13,151.19,7,94,0,7.52,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,156.98,7,8,0,13.12,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),5.03e-13,153.85,7,19,0,9.58,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.22e-11,151.01,7,21,0,9.33,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,156.19,7,12,0,11.08,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,163.91,7,10,0,11.9,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,156.49,7,10,0,11.9,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.27e-11,150.81,7,21,0,9.33,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),4.59e-13,152.42,7,21,0,9.33,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.9e-13,150.54,7,32,0,8.53,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,157.9,7,10,0,11.9,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.9e-13,156.87,7,39,0,8.26,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.9e-13,160.85,7,44,0,8.11,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.9e-13,153.72,7,113,0,7.43,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,151.25,7,11,0,11.45,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,150.98,7,11,0,11.45,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,151.44,7,12,0,11.08,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,149.33,7,25,0,8.96,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.9e-13,155.01,7,87,0,7.56,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.9e-13,150.0,7,33,0,8.48,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.9e-13,152.73,7,41,0,8.2,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.78e-13,152.9,7,21,0,9.33,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.02e-11,150.57,7,21,0,9.33,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.9e-13,151.51,7,1021,0,7.05,8.0
Body mass index (clna),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.49e-06,67.97,4,23,0,4.7,21.0
Body mass index (clna),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.49e-06,67.42,4,57,0,4.28,11.0
Body mass index (clna),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.78e-06,75.88,4,9,0,5.78,9.0
Body Weight (orga),ISA,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,50.31,55,22,0,30.8,5.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Hilum (bpoc),2.1e-12,25.59,16,56,0,20.57,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Neoplasm Metastasis (neop),2.19e-18,26.84,16,48,0,21.33,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Tumor Burden (diap),3.85e-15,28.72,16,28,0,25.14,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Primary Neoplasm (neop),1.07e-10,26.17,16,35,0,23.31,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Toxic effect (inpo),1.89e-19,25.21,16,145,0,17.77,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Decompensation (fndg),1.89e-19,27.71,16,224,0,17.14,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Hydrothorax (dsyn),7.51e-13,25.53,16,61,0,20.2,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Medical Imaging (diap),6.93e-09,23.87,16,3,0,3.56,2.0
Insulin (horm),PART_OF,Hepatic (blor),LOCATION_OF,Hepatic Veno-Occlusive Disease (dsyn),4.19e-07,26.73,16,19,0,29.47,2.0
Insulin Resistance (patf),CAUSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.6e-07,44.39,5,33,0,5.76,1.0
Insulin Resistance (patf),CAUSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.69e-06,44.93,5,16,0,6.56,9.0
Insulin Resistance (patf),CAUSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.6e-07,44.74,5,71,0,5.35,5.0
Insulin Resistance (patf),CAUSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.6e-07,58.58,5,35,0,5.71,11.0
Insulin Resistance (patf),CAUSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.6e-07,44.66,5,110,0,5.23,11.0
Insulin Resistance (patf),CAUSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),2.61e-07,44.0,5,37,0,5.68,1.0
Insulin (horm),AFFECTS,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.62e-07,46.95,5,5,0,10.0,3.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),USES,Medicare (rnlw),1.23e-06,21.11,6,20,0,7.8,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.23e-06,18.29,6,65,0,6.55,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),USES,Treats (clas),1.6e-06,20.61,6,16,0,8.25,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),5.32e-06,20.87,6,13,0,8.77,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),USES,Classification (clas),1.24e-06,21.85,6,16,0,8.25,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),4.7e-06,27.26,6,8,0,10.5,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.23e-06,20.73,6,23,0,7.57,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.23e-06,21.63,6,22,0,7.64,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),2.11e-06,21.56,6,13,0,8.77,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.23e-06,23.55,6,15,0,8.4,1.0
Physical activity (dora),TREATS,cohort (popg),USES,Medicare (rnlw),3.57e-08,24.66,7,20,0,9.45,4.0
Physical activity (dora),TREATS,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.73e-08,21.84,7,65,0,7.75,2.0
Physical activity (dora),TREATS,cohort (popg),USES,Treats (clas),4.1e-07,24.16,7,16,0,10.06,4.0
Physical activity (dora),TREATS,cohort (popg),LOCATION_OF,Calcium (bacs),4.13e-06,24.42,7,13,0,10.77,2.0
Physical activity (dora),TREATS,cohort (popg),USES,Classification (clas),4.7e-08,25.4,7,16,0,10.06,4.0
Physical activity (dora),TREATS,cohort (popg),LOCATION_OF,Sodium (elii),3.51e-06,30.81,7,8,0,13.12,2.0
Physical activity (dora),TREATS,cohort (popg),LOCATION_OF,C-reactive protein (aapp),3.49e-08,24.28,7,23,0,9.13,2.0
Physical activity (dora),TREATS,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),3.47e-08,25.18,7,22,0,9.23,2.0
Physical activity (dora),TREATS,cohort (popg),USES,Tissue Microarray (resd),9.19e-07,25.11,7,13,0,10.77,4.0
Physical activity (dora),TREATS,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.63e-08,27.1,7,15,0,10.27,2.0
abnormal glucose tolerance test (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,34.86,16,18,0,30.22,1.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hilum (bpoc),2.78e-08,36.57,6,56,0,6.64,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Neoplasm Metastasis (neop),2.78e-08,37.82,6,48,0,6.75,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Tumor Burden (diap),2.78e-08,39.7,6,28,0,7.29,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Primary Neoplasm (neop),2.79e-08,37.15,6,35,0,7.03,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Toxic effect (inpo),2.78e-08,36.19,6,145,0,6.25,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Decompensation (fndg),2.78e-08,38.69,6,224,0,6.16,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hydrothorax (dsyn),2.78e-08,36.51,6,61,0,6.59,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Medical Imaging (diap),3.47e-08,34.85,6,3,0,4.5,2.0
Fatty-acid synthase (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hepatic Veno-Occlusive Disease (dsyn),4.47e-07,37.71,6,19,0,7.89,2.0
Lower Extremity (blor),LOCATION_OF,Physical function (fndg),PROCESS_OF,Survivors (humn),2.17e-06,47.39,7,16,0,10.06,1.0
Abdominal obesity (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.39e-09,67.36,6,18,0,8.0,1.0
tomography (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),3.5e-09,36.35,7,18,0,9.72,6.0
Fitness (dora),TREATS,Participant (humn),USES,Medicare (rnlw),3.02e-06,57.18,4,18,0,4.89,4.0
Leptin|LEP (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",8.92e-10,58.58,29,79,0,39.65,1.0
Leptin|LEP (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.42e-06,58.54,29,29,0,58.0,1.0
insulin sensitivity (patf),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),3.01e-22,122.97,12,98,0,13.47,1.0
insulin sensitivity (patf),PROCESS_OF,African American (popg),ISA,Racial group (popg),3.01e-22,123.9,12,324,0,12.44,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,24.85,10,9,0,17.1,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),8.45e-11,23.91,10,194,0,10.52,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),4.21e-10,22.64,10,17,0,15.88,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),8.45e-11,23.9,10,29,0,13.45,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.84e-10,26.09,10,14,0,17.14,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,21.9,10,12,0,18.33,5.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),8.45e-11,20.72,10,48,0,12.08,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),8.45e-11,24.11,10,29,0,13.45,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.45e-11,21.15,10,98,0,11.02,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.41e-09,19.82,10,24,0,14.17,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,26.23,10,10,0,20.0,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,18.59,10,37,0,12.7,7.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.82e-09,20.39,10,20,0,15.0,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),8.45e-11,22.04,10,94,0,11.06,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,27.83,10,8,0,14.4,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),8.48e-11,24.71,10,19,0,15.26,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),9.65e-11,21.86,10,21,0,14.76,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.86e-09,27.04,10,12,0,18.33,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.72e-09,34.76,10,10,0,20.0,21.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.19e-08,27.34,10,10,0,20.0,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.07e-10,21.66,10,21,0,14.76,21.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),8.48e-11,23.27,10,21,0,14.76,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.45e-11,21.4,10,32,0,13.12,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.54e-08,28.76,10,10,0,20.0,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),8.45e-11,27.72,10,39,0,12.56,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),8.45e-11,31.7,10,44,0,12.27,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.45e-11,24.58,10,113,0,10.88,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,22.1,10,11,0,19.09,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,21.83,10,11,0,19.09,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,22.29,10,12,0,18.33,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),2.02e-10,20.19,10,25,0,14.0,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",8.45e-11,25.86,10,87,0,11.15,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),8.45e-11,20.85,10,33,0,13.03,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),8.45e-11,23.59,10,41,0,12.44,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.46e-11,23.75,10,21,0,14.76,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.34e-10,21.42,10,21,0,14.76,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),8.45e-11,22.37,10,1021,0,10.1,11.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hilum (bpoc),1.62e-06,29.35,5,56,0,5.45,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Neoplasm Metastasis (neop),1.62e-06,30.6,5,48,0,5.52,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Tumor Burden (diap),1.62e-06,32.48,5,28,0,5.89,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Primary Neoplasm (neop),1.62e-06,29.93,5,35,0,5.71,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Toxic effect (inpo),1.62e-06,28.96,5,145,0,5.17,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Decompensation (fndg),1.62e-06,31.47,5,224,0,5.11,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hydrothorax (dsyn),1.62e-06,29.28,5,61,0,5.41,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Medical Imaging (diap),1.63e-06,27.63,5,3,0,4.8,2.0
fibroblast growth factor 21|FGF21 (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hepatic Veno-Occlusive Disease (dsyn),2.04e-06,30.48,5,19,0,6.32,2.0
Insulin Resistance (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,47.92,15,18,0,27.5,1.0
Diet (food),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,48.62,18,16,0,30.22,9.0
Diet (food),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,53.79,18,9,0,13.5,9.0
Diet (food),CAUSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,46.17,18,31,0,28.45,11.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,64.24,19,20,0,37.05,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,61.42,19,65,0,24.55,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,63.74,19,16,0,29.47,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,64.0,19,13,0,21.89,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,64.98,19,16,0,29.47,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,70.39,19,8,0,11.37,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,63.86,19,23,0,34.7,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,64.76,19,22,0,35.41,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,64.69,19,13,0,21.89,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,66.69,19,15,0,26.84,1.0
Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),6.93e-08,14.71,9,18,0,13.5,1.0
TRANSCRIPTION FACTOR (aapp),PART_OF,Adipocytes (cell),PART_OF,Caucasoid Race (popg),9.06e-07,75.08,4,4,0,8.0,3.0
TRANSCRIPTION FACTOR (aapp),PART_OF,Adipocytes (cell),PART_OF,Stroma (bpoc),8.93e-07,75.11,4,7,0,6.29,3.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Amputation Stumps (acab),3.59e-10,11.14,13,86,0,14.97,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Head (blor),3.59e-10,9.58,13,629,0,13.27,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Neuroendocrine Tumors (neop),3.33e-09,11.1,13,23,0,20.35,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Cancer Diagnosis (diap),3.44e-06,10.15,13,21,0,21.05,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Neck (blor),3.59e-10,10.78,13,44,0,16.84,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Necrosis (patf),8.99e-07,10.37,13,21,0,21.05,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Anastomosis (acab),3.59e-10,12.73,13,79,0,15.14,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Nonpenetrating Wounds (inpo),1.74e-08,12.22,13,17,0,22.94,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Extravasation (patf),3.59e-10,11.75,13,86,0,14.97,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Pancreatitis (dsyn),3.59e-10,12.38,13,30,0,18.63,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Graft loss (patf),3.59e-10,13.72,13,30,0,18.63,2.0
Insulin (horm),PART_OF,Pancreas (bpoc),LOCATION_OF,Postoperative fistula (patf),3.59e-10,10.57,13,189,0,13.89,2.0
Diet (food),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),8.81e-07,77.42,4,33,0,4.48,1.0
Diet (food),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.31e-06,77.96,4,16,0,5.0,9.0
Diet (food),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),8.81e-07,77.77,4,71,0,4.23,5.0
Diet (food),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.81e-07,91.61,4,35,0,4.46,21.0
Diet (food),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.81e-07,77.69,4,110,0,4.15,21.0
Diet (food),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),8.82e-07,77.03,4,37,0,4.43,1.0
Amylin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",9.29e-08,150.3,4,79,0,4.2,1.0
Amylin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.51e-06,150.26,4,29,0,4.55,1.0
Oral Glucose Tolerance Test (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),3.94e-09,25.12,8,18,0,11.56,6.0
Adipose tissue (tisu),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),9.23e-18,45.51,28,45,0,45.42,2.0
Adipose tissue (tisu),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.06e-10,43.31,28,161,0,32.87,2.0
Adipose tissue (tisu),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.84e-07,43.43,28,81,0,37.68,2.0
European origin (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),2.56e-17,90.32,10,136,0,10.74,1.0
European origin (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),2.56e-17,89.45,10,188,0,10.53,1.0
European origin (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (popg),2.53e-06,90.34,10,20,0,15.0,1.0
Insulin Resistance (patf),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),4.25e-07,103.78,4,25,0,4.64,1.0
Insulin Resistance (patf),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),4.31e-07,101.58,4,13,0,5.23,1.0
Insulin Resistance (patf),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),4.25e-07,106.04,4,32,0,4.5,1.0
Assessment procedure (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,41.84,31,16,0,24.26,4.0
Assessment procedure (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,47.0,31,9,0,11.61,4.0
Assessment procedure (hlca),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,39.39,31,31,0,62.0,4.0
Aromatase (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),6.16e-09,100.54,5,5,0,10.0,3.0
Insulin|INS (gngm),AUGMENTS,Phosphorylation (moft),ISA,"Protein Processing, Post-Translational (moft)",3.67e-06,11.39,9,3,0,4.0,5.0
Waist circumference (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,112.44,34,18,0,27.53,1.0
Insulin Resistance (patf),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),7.74e-30,99.02,17,98,0,19.95,1.0
Insulin Resistance (patf),PROCESS_OF,African American (popg),ISA,Racial group (popg),3.65e-30,99.96,17,324,0,17.89,1.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.43e-08,147.18,5,13,0,6.92,16.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.4e-08,150.11,5,11,0,7.27,7.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),1.85e-09,151.32,5,13,0,6.92,16.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),1.51e-09,146.61,5,27,0,5.93,5.0
Fatty-acid synthase (gngm),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),2.72e-07,107.23,4,5,0,7.2,3.0
Leptin|LEP (aapp),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,173.18,6,16,0,8.25,9.0
Leptin|LEP (aapp),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,178.35,6,9,0,10.0,9.0
Leptin|LEP (aapp),CAUSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,170.74,6,31,0,7.16,11.0
Polycystic Ovary Syndrome (dsyn),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.68e-06,66.89,4,16,0,5.0,7.0
Polycystic Ovary Syndrome (dsyn),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),2.57e-06,72.05,4,9,0,5.78,7.0
Polycystic Ovary Syndrome (dsyn),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.75e-06,64.44,4,31,0,4.52,7.0
Insulin (horm),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),2e-08,76.09,5,5,0,10.0,3.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),2.14e-06,61.85,4,20,0,4.8,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.15e-06,59.03,4,65,0,4.25,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Treats (clas),2.52e-06,61.36,4,16,0,5.0,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),6.24e-06,61.61,4,13,0,5.23,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Classification (clas),2.15e-06,62.59,4,16,0,5.0,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),5.61e-06,68.0,4,8,0,6.0,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),2.14e-06,61.48,4,23,0,4.7,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),2.14e-06,62.37,4,22,0,4.73,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),3.03e-06,62.3,4,13,0,5.23,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.14e-06,64.3,4,15,0,5.07,1.0
Increased protein diet (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),3.6e-06,60.04,4,12,0,5.33,1.0
Increased protein diet (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),2.61e-06,57.41,4,24,0,4.67,4.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),4.25e-07,93.9,4,15,0,5.07,1.0
"TNF protein, human|TNF (aapp)",PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),4.21e-09,49.71,6,5,0,9.17,3.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),5.6e-07,88.85,4,29,0,4.55,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),1.27e-06,88.59,4,26,0,4.62,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),ISA,Medical Imaging (diap),2.82e-06,86.94,4,318,0,4.05,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),5.47e-07,92.07,4,129,0,4.12,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),ISA,Diagnosis (hlca),5.47e-07,87.71,4,112,0,4.14,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),5.61e-07,89.83,4,21,0,4.76,2.0
Fatty Liver (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.55e-10,47.93,7,23,0,9.13,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),2.76e-10,47.37,7,57,0,7.86,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,55.84,7,9,0,12.44,9.0
agonists (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),7.48e-08,58.67,5,33,0,5.76,1.0
agonists (phsu),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.51e-06,59.21,5,16,0,6.56,4.0
agonists (phsu),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),7.45e-08,59.01,5,71,0,5.35,4.0
agonists (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7.45e-08,72.86,5,35,0,5.71,4.0
agonists (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.45e-08,58.94,5,110,0,5.23,4.0
agonists (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),7.59e-08,58.28,5,37,0,5.68,1.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hilum (bpoc),2.65e-12,18.74,12,56,0,14.57,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Neoplasm Metastasis (neop),5.49e-13,19.98,12,48,0,15.0,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Tumor Burden (diap),5.53e-13,21.87,12,28,0,17.14,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Primary Neoplasm (neop),1.08e-10,19.31,12,35,0,16.11,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Toxic effect (inpo),5.49e-13,18.35,12,145,0,12.99,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Decompensation (fndg),5.49e-13,20.85,12,224,0,12.64,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hydrothorax (dsyn),1.3e-12,18.67,12,61,0,14.36,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Medical Imaging (diap),6.93e-09,17.02,12,3,0,3.75,2.0
Insulin|INS (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hepatic Veno-Occlusive Disease (dsyn),4.19e-07,19.87,12,19,0,19.58,2.0
Adiponectin (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,84.76,9,16,0,14.06,7.0
Adiponectin (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,89.93,9,9,0,18.0,7.0
Adiponectin (aapp),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,82.32,9,31,0,11.61,7.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.59e-10,41.75,29,33,0,54.48,1.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,42.3,29,16,0,24.83,9.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,42.1,29,71,0,40.85,5.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,55.95,29,35,0,53.03,9.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,42.03,29,110,0,36.65,9.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.35e-09,41.37,29,37,0,51.73,1.0
Diet (food),CAUSES,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.29e-10,83.71,6,62,0,6.58,11.0
Diet (food),CAUSES,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.29e-10,94.3,6,17,0,8.12,11.0
Diet (food),CAUSES,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.7e-10,86.0,6,19,0,7.89,9.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,23.81,13,9,0,15.23,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.18e-13,22.86,13,194,0,13.87,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,21.59,13,17,0,22.94,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.18e-13,22.86,13,29,0,18.83,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,25.04,13,14,0,25.07,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,20.85,13,12,0,23.08,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.18e-13,19.67,13,48,0,16.52,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.18e-13,23.06,13,29,0,18.83,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.18e-13,20.1,13,98,0,14.72,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,25.18,13,10,0,17.69,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,17.54,13,37,0,17.57,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,19.34,13,20,0,21.45,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.18e-13,20.99,13,94,0,14.8,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,26.78,13,8,0,12.92,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),4.31e-13,23.66,13,19,0,21.89,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.22e-11,20.81,13,21,0,21.05,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,25.99,13,12,0,23.08,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,33.71,13,10,0,17.69,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,26.3,13,10,0,17.69,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.26e-11,20.61,13,21,0,21.05,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.87e-13,22.22,13,21,0,21.05,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.18e-13,20.35,13,32,0,18.28,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,27.71,13,10,0,17.69,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.18e-13,26.68,13,39,0,17.33,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.18e-13,30.65,13,44,0,16.84,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.18e-13,23.53,13,113,0,14.5,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,21.06,13,11,0,20.31,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,20.78,13,11,0,20.31,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,21.24,13,12,0,23.08,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,19.14,13,25,0,19.76,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.18e-13,24.81,13,87,0,14.94,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.19e-13,19.8,13,33,0,18.12,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.18e-13,22.54,13,41,0,17.12,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.07e-13,22.71,13,21,0,21.05,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.01e-11,20.37,13,21,0,21.05,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.18e-13,21.32,13,1021,0,13.17,5.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),7.36e-06,216.08,3,11,0,3.82,8.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.18e-06,213.31,3,34,0,3.26,17.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),3.18e-06,217.67,3,20,0,3.45,17.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),ISA,Albumins (aapp),3.18e-06,214.91,3,30,0,3.3,5.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),3.31e-06,215.43,3,15,0,3.6,8.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),3.18e-06,212.49,3,77,0,3.12,5.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),compared_with,procalcitonin (aapp),3.2e-06,215.72,3,16,0,3.56,17.0
Triglycerides (bacs),compared_with,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),5.24e-06,214.76,3,14,0,3.64,17.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,74.87,7,9,0,12.44,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),2.15e-11,73.93,7,194,0,7.25,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.58e-10,72.65,7,17,0,9.88,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.15e-11,73.92,7,29,0,8.69,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.21e-10,76.1,7,14,0,10.5,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,71.91,7,12,0,11.08,5.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.15e-11,70.73,7,48,0,8.02,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),2.15e-11,74.12,7,29,0,8.69,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.15e-11,71.17,7,98,0,7.5,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.35e-09,69.83,7,24,0,9.04,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,76.24,7,10,0,11.9,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,68.6,7,37,0,8.32,7.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.75e-09,70.4,7,20,0,9.45,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),2.15e-11,72.06,7,94,0,7.52,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,77.85,7,8,0,13.12,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),2.18e-11,74.72,7,19,0,9.58,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),3.35e-11,71.88,7,21,0,9.33,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.8e-09,77.06,7,12,0,11.08,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.66e-09,84.77,7,10,0,11.9,21.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,77.36,7,10,0,11.9,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),4.4e-11,71.68,7,21,0,9.33,21.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.18e-11,73.29,7,21,0,9.33,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.15e-11,71.41,7,32,0,8.53,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,78.77,7,10,0,11.9,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.15e-11,77.74,7,39,0,8.26,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.15e-11,81.72,7,44,0,8.11,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.15e-11,74.59,7,113,0,7.43,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,72.12,7,11,0,11.45,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,71.85,7,11,0,11.45,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,72.31,7,12,0,11.08,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.39e-10,70.2,7,25,0,8.96,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",2.15e-11,75.88,7,87,0,7.56,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.15e-11,70.87,7,33,0,8.48,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),2.15e-11,73.6,7,41,0,8.2,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.16e-11,73.77,7,21,0,9.33,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",7.15e-11,71.44,7,21,0,9.33,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.15e-11,72.38,7,1021,0,7.05,11.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),4.02e-10,51.64,7,33,0,8.48,1.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,52.18,7,16,0,10.06,9.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.43e-10,51.98,7,71,0,7.69,5.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.43e-10,65.83,7,35,0,8.4,21.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.43e-10,51.91,7,110,0,7.45,21.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.5e-09,51.25,7,37,0,8.32,1.0
Fitness (dora),PREVENTS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.37e-06,243.54,3,33,0,3.27,1.0
Fitness (dora),PREVENTS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),6.8e-06,244.08,3,16,0,3.56,9.0
Fitness (dora),PREVENTS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.37e-06,243.88,3,71,0,3.13,5.0
Fitness (dora),PREVENTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.37e-06,257.73,3,35,0,3.26,21.0
Fitness (dora),PREVENTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.37e-06,243.81,3,110,0,3.08,21.0
Fitness (dora),PREVENTS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),2.37e-06,243.15,3,37,0,3.24,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Octogenarians (aggp),6.56e-07,385.25,4,9,0,5.78,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Surgical Patients (podg),1.85e-08,380.0,4,16,0,5.0,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,General Population (popg),6.22e-09,379.73,4,31,0,4.52,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),6.22e-09,379.15,4,28,0,4.57,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,African American (popg),6.22e-09,381.66,4,53,0,4.3,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Caucasoid Race (popg),1.25e-06,377.79,4,19,0,4.84,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),6.22e-09,379.56,4,33,0,4.48,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Long-Term Survivors (podg),7.07e-09,380.59,4,17,0,4.94,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),6.22e-09,377.25,4,100,0,4.16,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),ISA,Common Neoplasm (neop),9.87e-09,378.91,4,20,0,4.8,5.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (popg),7.4e-08,378.68,4,18,0,4.89,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (popg),6.22e-09,378.93,4,63,0,4.25,1.0
Waist circumference (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Black race (popg),2.84e-08,380.98,4,14,0,5.14,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,37.64,12,16,0,21.0,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,42.81,12,9,0,15.75,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,35.19,12,31,0,16.65,9.0
Magnetic Resonance Spectroscopy (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),3.75e-08,80.03,8,18,0,11.56,16.0
Magnetic Resonance Spectroscopy (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),2.51e-07,85.31,8,10,0,14.4,16.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,70.15,9,16,0,14.06,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,75.31,9,9,0,18.0,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,67.7,9,31,0,11.61,8.0
Fatty deposition (patf),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.06e-07,177.5,4,16,0,5.0,9.0
Fatty deposition (patf),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.99e-07,182.67,4,9,0,5.78,9.0
Fatty deposition (patf),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.77e-07,175.05,4,31,0,4.52,9.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),1.01e-09,24.31,10,20,0,15.0,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.55e-09,21.5,10,65,0,11.54,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Treats (clas),3.76e-07,23.82,10,16,0,16.25,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,24.07,10,13,0,17.69,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Classification (clas),1.23e-08,25.06,10,16,0,16.25,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,30.46,10,8,0,14.4,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.93e-10,23.94,10,23,0,14.35,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),3.1e-11,24.83,10,22,0,14.55,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,24.76,10,13,0,17.69,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.56e-09,26.76,10,15,0,16.67,1.0
"Leukemia, Lymphocytic, Acute (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),3.31e-17,34.63,14,25,0,21.84,1.0
"Leukemia, Lymphocytic, Acute (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,32.43,14,13,0,25.07,1.0
"Leukemia, Lymphocytic, Acute (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),3.29e-17,36.89,14,32,0,20.12,1.0
Entire lumbar spine (blor),LOCATION_OF,Magnetic Resonance Spectroscopy (diap),USES,Mandibular right second molar prosthesis (medd),4.38e-06,187.61,3,3,0,6.0,2.0
Entire lumbar spine (blor),LOCATION_OF,Magnetic Resonance Spectroscopy (diap),USES,Protons (elii),4.11e-06,187.66,3,35,0,3.26,2.0
Stem cells (cell),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.81e-07,24.52,6,5,0,9.17,3.0
"Fatty Acids, Nonesterified (lipd)",CAUSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.77e-08,25.91,8,16,0,12.0,9.0
"Fatty Acids, Nonesterified (lipd)",CAUSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.41e-07,31.07,8,9,0,15.11,9.0
"Fatty Acids, Nonesterified (lipd)",CAUSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.19e-07,23.46,8,31,0,10.06,11.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.37e-08,25.57,7,18,0,9.72,1.0
Adipocytes (cell),LOCATION_OF,Norepinephrine (nsba),ASSOCIATED_WITH,Septic Shock (patf),6.94e-07,38.61,5,25,0,6.0,2.0
Adipocytes (cell),LOCATION_OF,Norepinephrine (nsba),ISA,Vasoconstrictor Agents (phsu),6.94e-07,36.76,5,35,0,5.71,2.0
Adipocytes (cell),LOCATION_OF,Norepinephrine (nsba),CAUSES,Contraction (patf),6.94e-07,33.51,5,1,0,1.2,2.0
Adipocytes (cell),LOCATION_OF,Norepinephrine (nsba),TREATS,Septic Shock (patf),6.94e-07,38.86,5,31,0,5.81,2.0
macrophage (cell),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,30.85,37,5,0,5.68,3.0
Subcutaneous Fat (tisu),PART_OF,Entire trunk (bpoc),LOCATION_OF,Hemorrhage (fndg),1.7e-07,115.57,13,12,0,23.08,2.0
Subcutaneous Fat (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Elephants (mamm),1.33e-23,113.89,13,140,0,14.21,3.0
Subcutaneous Fat (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Aorta (bpoc),2.04e-09,111.29,13,35,0,17.83,3.0
Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),USES,"Defibrillators, Implantable (medd)",4.63e-07,28.64,6,149,0,6.24,6.0
Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),USES,Hydroxymethylglutaryl-CoA Reductase Inhibitors (phsu),4.63e-07,24.33,6,61,0,6.59,6.0
Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),USES,Aspirin (phsu),4.63e-07,23.77,6,79,0,6.46,6.0
"Fatty Acids, Nonesterified (lipd)",PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.65e-07,54.61,5,16,0,6.56,9.0
"Fatty Acids, Nonesterified (lipd)",PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.06e-06,59.77,5,9,0,7.78,9.0
"Fatty Acids, Nonesterified (lipd)",PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.37e-07,52.16,5,31,0,5.81,21.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.59e-10,50.49,17,33,0,25.76,1.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,51.03,17,16,0,31.06,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.21e-25,50.84,17,71,0,21.07,5.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.88e-25,64.68,17,35,0,25.26,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.88e-25,50.76,17,110,0,19.63,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.35e-09,50.1,17,37,0,24.81,1.0
tomography (diap),METHOD_OF,Magnetic Resonance Spectroscopy (diap),USES,Mandibular right second molar prosthesis (medd),2.72e-07,450.2,4,3,0,5.25,6.0
tomography (diap),METHOD_OF,Magnetic Resonance Spectroscopy (diap),USES,Protons (elii),3.82e-09,450.26,4,35,0,4.46,6.0
Adipocytes (cell),PART_OF,Epididymis (bpoc),LOCATION_OF,Localized adiposity (fndg),2.15e-06,21.34,16,2,0,2.25,2.0
Adipocytes (cell),LOCATION_OF,Isoproterenol (orch),ISA,Adrenergic beta-Agonists (phsu),4.98e-07,36.15,5,9,0,7.78,2.0
Entire intervertebral space (bsoj),LOCATION_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),3.2e-06,213.28,3,29,0,3.31,2.0
Entire intervertebral space (bsoj),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),3.91e-06,213.02,3,26,0,3.35,2.0
Entire intervertebral space (bsoj),LOCATION_OF,tomography (diap),ISA,Medical Imaging (diap),5.46e-06,211.37,3,318,0,3.03,2.0
Entire intervertebral space (bsoj),LOCATION_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),3.18e-06,216.5,3,129,0,3.07,2.0
Entire intervertebral space (bsoj),LOCATION_OF,tomography (diap),ISA,Diagnosis (hlca),3.18e-06,212.14,3,112,0,3.08,2.0
Entire intervertebral space (bsoj),LOCATION_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),3.2e-06,214.26,3,21,0,3.43,2.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,159.44,16,20,0,28.8,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,156.62,16,65,0,19.94,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,158.94,16,16,0,32.0,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,159.2,16,13,0,23.56,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,160.18,16,16,0,32.0,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,165.59,16,8,0,12.0,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,159.06,16,23,0,27.13,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,159.96,16,22,0,27.64,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,159.89,16,13,0,23.56,1.0
Waist circumference (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,161.88,16,15,0,29.06,1.0
Subcutaneous Fat (tisu),PART_OF,Limb structure (bpoc),LOCATION_OF,Fracture (inpo),9.69e-08,151.46,4,56,0,4.29,2.0
Subcutaneous Fat (tisu),PART_OF,Limb structure (bpoc),LOCATION_OF,sarcoma (neop),2.8e-06,153.38,4,15,0,5.07,2.0
Subcutaneous Fat (tisu),PART_OF,Limb structure (bpoc),LOCATION_OF,Necrotizing fasciitis (dsyn),1.68e-07,157.02,4,12,0,5.33,2.0
Adipose tissue (tisu),LOCATION_OF,Interleukin-6 (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),2.7e-06,34.3,5,10,0,7.5,2.0
Adipose tissue (tisu),LOCATION_OF,Interleukin-6 (aapp),ASSOCIATED_WITH,Septicemia (dsyn),5.31e-06,30.05,5,15,0,6.67,2.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.6e-08,56.89,7,16,0,10.06,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,62.06,7,9,0,12.44,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,54.44,7,31,0,8.58,9.0
Face (blor),LOCATION_OF,Wasting (dsyn),PROCESS_OF,"Energy, Physics (npop)",3.85e-07,204.08,5,18,0,6.39,1.0
Adipose tissue (tisu),LOCATION_OF,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,28.19,15,2,0,2.27,2.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),4.35e-06,56.89,4,25,0,4.64,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),4.36e-06,54.69,4,13,0,5.23,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),4.35e-06,59.15,4,32,0,4.5,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,74.11,14,16,0,26.25,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,79.27,14,9,0,14.79,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,71.66,14,31,0,20.32,8.0
Energy Metabolism (phsf),PROCESS_OF,Hypothalamic structure (bpoc),LOCATION_OF,Entire paraventricular nucleus (blor),1.63e-06,62.59,4,10,0,5.6,1.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.11e-08,58.27,9,15,0,14.4,1.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",8.49e-14,54.75,9,60,0,10.35,1.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.19e-12,55.62,9,33,0,11.45,1.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),8.25e-14,54.27,9,357,0,9.23,1.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),3.75e-08,196.29,13,18,0,22.39,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),2.51e-07,201.57,13,10,0,17.69,16.0
Insulin Resistance (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,32.32,14,23,0,22.52,9.0
Insulin Resistance (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),4.65e-18,31.77,14,57,0,17.44,9.0
Insulin Resistance (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,40.23,14,9,0,14.79,9.0
Body mass index procedure (diap),AFFECTS,Systolic blood pressure (ortf),PROCESS_OF,cohort (popg),3.5e-06,63.28,8,15,0,12.27,1.0
Body mass index procedure (diap),AFFECTS,Systolic blood pressure (ortf),PROCESS_OF,Survivors (humn),1.56e-09,69.03,8,13,0,12.92,1.0
Leptin|LEP (aapp),AFFECTS,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.34e-10,96.52,6,5,0,9.17,3.0
High Density Lipoprotein Cholesterol (bacs),ISA,Cholesterol (bacs),PART_OF,Membrane (celc),6.47e-15,16.37,20,5,0,6.25,3.0
Subcutaneous Fat (tisu),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),9.23e-18,48.87,32,45,0,54.76,2.0
Subcutaneous Fat (tisu),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.06e-10,46.67,32,161,0,38.36,2.0
Subcutaneous Fat (tisu),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.84e-07,46.79,32,81,0,44.64,2.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.2e-14,444.89,21,22,0,41.05,8.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,444.31,21,17,0,30.76,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),1.29e-08,440.38,21,27,0,37.33,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,443.34,21,15,0,25.71,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,441.54,21,24,0,39.38,8.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),8.91e-14,441.16,21,34,0,33.97,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (popg),5.21e-21,442.58,21,40,0,32.02,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,449.31,21,12,0,18.86,8.0
Overweight (sosy),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),7.45e-08,58.62,5,98,0,5.26,1.0
Overweight (sosy),PROCESS_OF,African American (popg),ISA,Racial group (popg),7.45e-08,59.56,5,324,0,5.08,1.0
Adipose tissue (tisu),LOCATION_OF,Glucocorticoids (horm),TREATS,"Respiratory Distress Syndrome, Adult (dsyn)",4.24e-08,91.27,8,13,0,12.92,2.0
Lipoproteins (aapp),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),8.02e-07,8.42,11,2,0,2.36,3.0
resistin|RETN (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,54.7,11,16,0,18.56,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,59.87,11,9,0,16.36,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,52.25,11,31,0,14.9,8.0
Total cholesterol (strd),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),1.04e-06,15.02,7,2,0,2.57,3.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),1.18e-07,155.14,4,15,0,5.07,21.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),1.35e-07,157.5,4,12,0,5.33,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),9.89e-08,155.8,4,15,0,5.07,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),9.2e-08,155.04,4,28,0,4.57,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),9.2e-08,153.2,4,28,0,4.57,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),9.2e-08,155.99,4,66,0,4.24,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),9.2e-08,153.84,4,47,0,4.34,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),9.21e-08,153.13,4,27,0,4.59,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),9.87e-07,157.55,4,10,0,5.6,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),9.62e-08,158.12,4,13,0,5.23,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",9.2e-08,153.54,4,26,0,4.62,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),2.35e-07,153.19,4,19,0,4.84,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.95e-07,154.55,4,15,0,5.07,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (popg),9.28e-08,153.47,4,23,0,4.7,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.22e-06,153.08,4,16,0,5.0,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.23e-06,154.23,4,13,0,5.23,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.44e-06,152.94,4,17,0,4.94,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (popg),9.2e-08,153.58,4,51,0,4.31,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),9.2e-08,154.07,4,145,0,4.11,11.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),9.2e-08,154.93,4,39,0,4.41,11.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (popg),3.51e-06,154.55,4,12,0,5.33,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.86e-06,153.7,4,14,0,5.14,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",7.55e-07,157.88,4,10,0,5.6,9.0
Triglycerides (bacs),COEXISTS_WITH,Insulin (horm),TREATS,Hospitalized Patients (podg),2.75e-06,85.74,6,11,0,9.27,4.0
Triglycerides (bacs),COEXISTS_WITH,Insulin (horm),TREATS,Hyperglycemia (dsyn),3.29e-10,83.53,6,57,0,6.63,4.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),1.39e-08,16.32,9,20,0,13.05,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.54e-08,13.5,9,65,0,10.25,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),USES,Treats (clas),3.88e-07,15.82,9,16,0,14.06,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.11e-06,16.08,9,13,0,15.23,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),USES,Classification (clas),2.51e-08,17.06,9,16,0,14.06,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.48e-06,22.47,9,8,0,15.11,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.31e-08,15.94,9,23,0,12.52,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.29e-08,16.84,9,22,0,12.68,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.97e-07,16.77,9,13,0,15.23,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.44e-08,18.76,9,15,0,14.4,1.0
olanzapine (orch),ISA,Antipsychotic Agents (phsu),TREATS,Dementia (mobd),8.11e-15,17.2,15,46,0,19.89,4.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),1e-09,97.93,7,20,0,9.45,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,95.12,7,65,0,7.75,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,97.44,7,16,0,10.06,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,97.69,7,13,0,10.77,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,98.67,7,16,0,10.06,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,104.08,7,8,0,13.12,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.79e-10,97.56,7,23,0,9.13,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.79e-11,98.45,7,22,0,9.23,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,98.38,7,13,0,10.77,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.55e-09,100.38,7,15,0,10.27,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),3.62e-08,208.75,4,20,0,4.8,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.77e-08,205.94,4,65,0,4.25,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),USES,Treats (clas),4.11e-07,208.26,4,16,0,5.0,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.13e-06,208.51,4,13,0,5.23,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),USES,Classification (clas),4.74e-08,209.49,4,16,0,5.0,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.51e-06,214.9,4,8,0,6.0,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),3.54e-08,208.38,4,23,0,4.7,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),3.52e-08,209.27,4,22,0,4.73,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),9.2e-07,209.2,4,13,0,5.23,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.67e-08,211.2,4,15,0,5.07,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),1.19e-06,32.01,5,33,0,5.76,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.62e-06,32.56,5,16,0,6.56,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.18e-06,32.36,5,71,0,5.35,5.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.18e-06,46.2,5,35,0,5.71,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-06,32.29,5,110,0,5.23,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.19e-06,31.62,5,37,0,5.68,1.0
Energy Metabolism (phsf),PROCESS_OF,Chamber (bpoc),LOCATION_OF,Pathological Dilatation (patf),5.41e-08,40.69,7,25,0,8.96,1.0
Clamp (medd),USES,Insulin (horm),TREATS,Hospitalized Patients (podg),2.75e-06,23.27,12,11,0,21.08,4.0
Clamp (medd),USES,Insulin (horm),TREATS,Hyperglycemia (dsyn),3.02e-13,21.05,12,57,0,14.53,4.0
Exercise (dora),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.28e-06,55.52,4,16,0,5.0,9.0
Exercise (dora),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),4.18e-06,60.69,4,9,0,5.78,9.0
Exercise (dora),PREVENTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),3.35e-06,53.07,4,31,0,4.52,21.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),1.19e-06,349.34,3,15,0,3.6,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.19e-06,351.81,3,15,0,3.6,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",1.19e-06,343.31,3,20,0,3.45,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.19e-06,342.58,3,52,0,3.17,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (podg),1.75e-06,341.45,3,15,0,3.6,1.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.2e-06,340.97,3,21,0,3.43,1.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),1.19e-06,342.26,3,51,0,3.18,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),1.27e-06,344.57,3,12,0,3.75,1.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),1.19e-06,346.91,3,15,0,3.6,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),1.19e-06,344.16,3,43,0,3.21,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),1.2e-06,344.41,3,14,0,3.64,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.19e-06,342.58,3,26,0,3.35,8.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (popg),1.19e-06,341.77,3,22,0,3.41,1.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),2.82e-06,338.95,3,43,0,3.21,5.0
adiposity (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (popg),1.19e-06,341.4,3,44,0,3.2,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",7.48e-07,84.75,4,16,0,5.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.64e-06,89.92,4,9,0,5.78,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),8.2e-07,82.3,4,31,0,4.52,8.0
Energy Metabolism (phsf),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",1.2e-07,50.49,5,79,0,5.32,1.0
Energy Metabolism (phsf),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.54e-06,50.45,5,29,0,5.86,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,41.64,10,16,0,16.25,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,46.81,10,9,0,17.1,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,39.19,10,31,0,13.23,8.0
Diet (food),CAUSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),4.12e-10,51.03,7,33,0,8.48,1.0
Diet (food),CAUSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,51.57,7,16,0,10.06,9.0
Diet (food),CAUSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.54e-10,51.38,7,71,0,7.69,5.0
Diet (food),CAUSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.54e-10,65.22,7,35,0,8.4,11.0
Diet (food),CAUSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.54e-10,51.3,7,110,0,7.45,11.0
Diet (food),CAUSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.51e-09,50.64,7,37,0,8.32,1.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.59e-10,109.59,8,33,0,9.94,1.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,110.13,8,16,0,12.0,8.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.9e-14,109.94,8,71,0,8.9,5.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.9e-14,123.78,8,35,0,9.83,8.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.9e-14,109.86,8,110,0,8.58,8.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.35e-09,109.2,8,37,0,9.73,1.0
Visceral Fat (tisu),PART_OF,Caucasoid Race (popg),ISA,Racial group (popg),9.2e-08,152.43,4,136,0,4.12,3.0
Visceral Fat (tisu),PART_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),9.2e-08,151.56,4,188,0,4.09,3.0
Visceral Fat (tisu),PART_OF,Caucasoid Race (popg),ISA,Population Group (popg),2.63e-06,152.45,4,20,0,4.8,3.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),6.7e-06,195.66,3,9,0,4.0,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),4.11e-06,194.71,3,194,0,3.05,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),4.11e-06,193.44,3,17,0,3.53,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),4.11e-06,194.71,3,29,0,3.31,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),4.11e-06,196.89,3,14,0,3.64,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),5.18e-06,192.7,3,12,0,3.75,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),4.11e-06,191.52,3,48,0,3.19,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),4.11e-06,194.91,3,29,0,3.31,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.11e-06,191.95,3,98,0,3.09,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),4.12e-06,190.62,3,24,0,3.38,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),4.29e-06,197.03,3,10,0,3.9,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),4.13e-06,189.39,3,37,0,3.24,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),4.12e-06,191.19,3,20,0,3.45,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),4.11e-06,192.84,3,94,0,3.1,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),6.46e-06,198.63,3,8,0,4.12,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),4.11e-06,195.51,3,19,0,3.47,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),4.11e-06,192.66,3,21,0,3.43,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),4.12e-06,197.84,3,12,0,3.75,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.12e-06,205.56,3,10,0,3.9,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),4.19e-06,198.15,3,10,0,3.9,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),4.11e-06,192.46,3,21,0,3.43,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),4.11e-06,194.07,3,21,0,3.43,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.11e-06,192.2,3,32,0,3.28,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),4.15e-06,199.56,3,10,0,3.9,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.11e-06,198.53,3,39,0,3.23,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),4.11e-06,202.5,3,44,0,3.2,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.11e-06,195.38,3,113,0,3.08,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),6.86e-06,192.91,3,11,0,3.82,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),8.29e-06,192.63,3,11,0,3.82,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),4.67e-06,193.09,3,12,0,3.75,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),4.11e-06,190.99,3,25,0,3.36,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",4.11e-06,196.66,3,87,0,3.1,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),4.11e-06,191.65,3,33,0,3.27,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),4.11e-06,194.39,3,41,0,3.22,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),4.11e-06,194.56,3,21,0,3.43,1.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",4.11e-06,192.22,3,21,0,3.43,4.0
Caloric Restriction (topp),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),4.11e-06,193.17,3,1021,0,3.01,4.0
neuropeptide Y|NPY (aapp),PART_OF,Hypothalamic structure (bpoc),LOCATION_OF,Entire paraventricular nucleus (blor),4.2e-09,28.83,7,10,0,11.9,2.0
Australian origin (fndg),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),1.49e-06,68.45,4,20,0,4.8,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.49e-06,65.63,4,65,0,4.25,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),USES,Treats (clas),1.87e-06,67.95,4,16,0,5.0,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),5.58e-06,68.21,4,13,0,5.23,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),USES,Classification (clas),1.5e-06,69.19,4,16,0,5.0,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),4.96e-06,74.6,4,8,0,6.0,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.49e-06,68.07,4,23,0,4.7,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.49e-06,68.97,4,22,0,4.73,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),2.37e-06,68.9,4,13,0,5.23,1.0
Australian origin (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.49e-06,70.89,4,15,0,5.07,1.0
Overweight (sosy),PREDISPOSES,Dementia (mobd),PROCESS_OF,cohort (popg),4.2e-09,170.69,6,38,0,6.95,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),3.95e-08,22.49,7,33,0,8.48,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.47e-06,23.04,7,16,0,10.06,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.92e-08,22.84,7,71,0,7.69,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.92e-08,36.68,7,35,0,8.4,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.92e-08,22.77,7,110,0,7.45,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),4.06e-08,22.1,7,37,0,8.32,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.67e-06,63.27,5,9,0,7.78,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),8.01e-08,62.33,5,194,0,5.13,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),8.04e-08,61.05,5,17,0,6.47,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),8.01e-08,62.32,5,29,0,5.86,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),8.03e-08,64.5,5,14,0,6.79,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.14e-06,60.31,5,12,0,7.08,5.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),8.01e-08,59.13,5,48,0,5.52,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),8.01e-08,62.52,5,29,0,5.86,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.01e-08,59.57,5,98,0,5.26,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),8.24e-08,58.23,5,24,0,6.04,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.56e-07,64.64,5,10,0,7.5,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),9.22e-08,57.0,5,37,0,5.68,7.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),8.68e-08,58.8,5,20,0,6.25,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),8.01e-08,60.46,5,94,0,5.27,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.42e-06,66.25,5,8,0,8.12,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),8.01e-08,63.12,5,19,0,6.32,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),8.01e-08,60.28,5,21,0,6.19,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),8.28e-08,65.46,5,12,0,7.08,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.27e-08,73.17,5,10,0,7.5,21.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.62e-07,65.76,5,10,0,7.5,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),8.01e-08,60.08,5,21,0,6.19,21.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),8.01e-08,61.69,5,21,0,6.19,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.01e-08,59.81,5,32,0,5.78,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.15e-07,67.17,5,10,0,7.5,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),8.01e-08,66.14,5,39,0,5.64,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),8.01e-08,70.12,5,44,0,5.57,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.01e-08,62.99,5,113,0,5.22,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.83e-06,60.52,5,11,0,7.27,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.25e-06,60.25,5,11,0,7.27,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),6.39e-07,60.71,5,12,0,7.08,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),8.02e-08,58.6,5,25,0,6.0,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",8.01e-08,64.28,5,87,0,5.29,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),8.01e-08,59.27,5,33,0,5.76,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),8.01e-08,62.0,5,41,0,5.61,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.01e-08,62.17,5,21,0,6.19,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",8.01e-08,59.84,5,21,0,6.19,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),8.01e-08,60.78,5,1021,0,5.02,11.0
Induction (topp),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),3.18e-06,213.39,3,33,0,3.27,1.0
Induction (topp),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),7.62e-06,213.94,3,16,0,3.56,4.0
Induction (topp),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.18e-06,213.74,3,71,0,3.13,4.0
Induction (topp),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.18e-06,227.58,3,35,0,3.26,4.0
Induction (topp),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.18e-06,213.67,3,110,0,3.08,4.0
Induction (topp),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),3.19e-06,213.0,3,37,0,3.24,1.0
Lipase (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.18e-10,51.21,7,5,0,8.57,3.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.76e-07,43.77,5,33,0,5.76,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.71e-06,44.32,5,16,0,6.56,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.76e-07,44.12,5,71,0,5.35,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.76e-07,57.96,5,35,0,5.71,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.76e-07,44.05,5,110,0,5.23,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),2.78e-07,43.38,5,37,0,5.68,1.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),TREATS,Septic Shock (patf),6.61e-09,36.11,7,15,0,10.27,4.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),ASSOCIATED_WITH,Septic Shock (patf),4.9e-08,33.12,7,13,0,10.77,8.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),TREATS,Septicemia (dsyn),6.58e-09,37.09,7,16,0,10.06,4.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),TREATS,Septic Shock (patf),6.67e-09,36.88,7,14,0,10.5,4.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),1.82e-09,71.67,6,20,0,7.8,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.36e-09,68.85,6,65,0,6.55,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),USES,Treats (clas),3.76e-07,71.17,6,16,0,8.25,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.1e-06,71.43,6,13,0,8.77,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),USES,Classification (clas),1.31e-08,72.41,6,16,0,8.25,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,77.82,6,8,0,10.5,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),9.95e-10,71.29,6,23,0,7.57,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),8.33e-10,72.19,6,22,0,7.64,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,72.12,6,13,0,8.77,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.36e-09,74.12,6,15,0,8.4,1.0
Adipose tissue (tisu),LOCATION_OF,Insulin (horm),TREATS,Hospitalized Patients (podg),2.75e-06,45.34,13,11,0,20.31,2.0
Adipose tissue (tisu),LOCATION_OF,Insulin (horm),TREATS,Hyperglycemia (dsyn),1.66e-18,43.13,13,57,0,15.96,2.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Males (popg),4.04e-10,14.3,21,38,0,32.61,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Surgical Patients (podg),4.04e-10,13.37,21,45,0,30.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Malnutrition (dsyn),4.04e-10,14.54,21,17,0,30.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),4.04e-10,9.61,21,26,0,37.96,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Infant, Premature (humn)",4.07e-10,11.14,21,18,0,33.43,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Animalia (anim),4.04e-10,5.65,21,53,0,29.32,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),COEXISTS_WITH,Glomerular Filtration Rate (ortf),2.26e-09,14.41,21,12,0,18.86,9.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Ischemic stroke (dsyn),5.22e-07,10.21,21,11,0,16.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Respiratory Distress Syndrome, Adult (dsyn)",6.51e-07,13.74,21,9,0,12.86,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Ischemia (dsyn),2.39e-06,7.31,21,14,0,23.33,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Apgar Score (orga),2.91e-07,15.18,21,9,0,12.86,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Proteinuria (dsyn),2.34e-06,14.69,21,8,0,11.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Survivors (humn),4.04e-10,11.23,21,22,0,41.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,African race (popg),4.05e-10,14.28,21,16,0,28.19,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,General Population (popg),4.04e-10,13.43,21,30,0,35.7,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Cancer Patient (podg),7.5e-10,8.05,21,20,0,39.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Surgical Patients (podg),5.48e-08,14.86,21,10,0,14.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,parent (humn),4.08e-10,8.69,21,22,0,41.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,member (popg),4.05e-10,10.16,21,20,0,39.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Rural Population (popg),1.87e-07,16.07,21,9,0,12.86,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Liver Failure, Acute (dsyn)",1.11e-06,9.61,21,11,0,16.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Japanese Population (popg),1.18e-07,17.11,21,9,0,12.86,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),4.04e-10,15.48,21,29,0,36.21,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Males (popg),4.15e-10,16.21,21,14,0,23.33,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pulmonary arterial hypertension (dsyn),8.95e-09,12.61,21,12,0,18.86,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Human Age Group (aggp),4.04e-10,14.0,21,75,0,26.88,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",4.04e-10,13.11,21,48,0,30.19,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,American (popg),4.04e-10,9.61,21,22,0,41.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),6.78e-10,11.32,21,15,0,25.71,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,VICTIM (popg),4.04e-10,10.54,21,62,0,28.11,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,cohort (popg),4.04e-10,15.36,21,124,0,24.56,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Racial group (popg),4.05e-10,13.17,21,17,0,30.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Black race (popg),4.04e-10,11.81,21,41,0,31.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Physicians (humn),3.5e-06,6.61,21,16,0,28.19,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Myocardial Infarction (dsyn),4.04e-10,10.29,21,46,0,30.59,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Larva (invt),4.41e-10,7.07,21,26,0,37.96,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Participant (humn),4.04e-10,13.67,21,138,0,24.2,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Population Group (popg),4.04e-10,15.07,21,35,0,33.6,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Pregnant Women (popg),4.55e-10,9.72,21,18,0,33.43,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Survivors (humn),4.04e-10,11.68,21,135,0,24.27,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Long-Term Survivors (podg),7.65e-08,10.58,21,12,0,18.86,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,sex (orga),2.34e-06,14.69,21,8,0,11.05,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pancreatitis (dsyn),4.04e-10,11.99,21,27,0,37.33,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Western society (popg),4.67e-08,6.79,21,20,0,39.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Primary carcinoma of the liver cells (neop),4.4e-07,14.41,21,9,0,12.86,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Black race (popg),6.03e-07,18.01,21,8,0,11.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Fishes (fish),1.56e-09,8.44,21,18,0,33.43,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,hypoglycemia (dsyn),8.95e-07,11.11,21,10,0,14.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Youth (aggp),3.68e-09,7.17,21,21,0,42.0,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Infant, Premature (humn)",4.04e-10,10.59,21,64,0,27.89,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Middle Aged (aggp),4.04e-10,11.17,21,21,0,42.0,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,heart rate (orga),2.34e-06,14.69,21,8,0,11.05,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Renal function (ortf),3.29e-08,13.04,21,11,0,16.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Cardiomyopathies (dsyn),3.46e-06,9.82,21,10,0,14.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Sickle Cell Anemia (dsyn),7.65e-08,10.58,21,12,0,18.86,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Physical findings (sosy),8.09e-10,12.3,21,14,0,23.33,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Respiration Disorders (dsyn),1.53e-06,15.61,21,8,0,11.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Seizures (sosy),6.95e-07,9.01,21,12,0,18.86,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Recipient, Transplant (humn)",4.04e-10,11.8,21,131,0,24.37,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Donor person (humn),4.05e-10,7.34,21,28,0,36.75,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Septicemia (dsyn),4.04e-10,11.92,21,66,0,27.68,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,high-risk group (popg),4.04e-10,13.77,21,22,0,41.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Girls (popg),4.39e-06,9.61,21,10,0,14.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Heart failure (dsyn),4.04e-10,13.23,21,85,0,26.19,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,STEMI (dsyn),1.18e-07,17.11,21,9,0,12.86,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Human Age Group (aggp),4.97e-10,15.93,21,13,0,21.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),OCCURS_IN,year (tmco),4.04e-10,10.13,21,21,0,42.0,11.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Teens (popg),3.35e-07,8.7,21,13,0,21.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Vasculitis (dsyn),3.47e-06,13.9,21,8,0,11.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Veterans (popg),4.04e-10,13.79,21,26,0,37.96,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Females (popg),4.04e-10,13.0,21,24,0,39.38,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Hospitalized Patients (podg),4.04e-10,10.93,21,74,0,26.96,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Older Population (popg),3.18e-09,13.9,21,12,0,18.86,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Heart Diseases (dsyn),4.08e-10,10.97,21,18,0,33.43,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Boys (popg),1.11e-06,9.61,21,11,0,16.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Hypertension, Pulmonary (dsyn)",2.36e-08,11.61,21,12,0,18.86,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Infant, Very Low Birth Weight (dsyn)",4.04e-10,13.61,21,20,0,39.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,athlete (humn),4.05e-10,8.92,21,23,0,40.17,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Recipient, Transplant (humn)",4.04e-10,12.85,21,19,0,36.19,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,End stage renal failure (dsyn),4.04e-10,15.09,21,37,0,32.92,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Alaska Native (popg),4.86e-07,11.79,21,10,0,14.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Male gender (orga),2.26e-09,14.41,21,12,0,18.86,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Influenza (dsyn),2.29e-07,10.94,21,11,0,16.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Lupus Erythematosus, Systemic (dsyn)",4.05e-10,11.21,21,19,0,36.19,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Acquired Immunodeficiency Syndrome (dsyn),4.04e-10,9.06,21,23,0,40.17,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Prisoners (popg),3.18e-09,13.9,21,12,0,18.86,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Population Group (popg),4.04e-10,15.99,21,33,0,34.36,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),OCCURS_IN,month (tmco),4.04e-10,11.95,21,19,0,36.19,11.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pulmonary Embolism (dsyn),4.04e-10,13.61,21,20,0,39.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Control Groups (humn),4.04e-10,11.04,21,71,0,27.21,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,cohort (popg),4.04e-10,15.81,21,625,0,21.71,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Felis catus (mamm),3.27e-08,7.38,21,18,0,33.43,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Workers (popg),4.04e-10,10.03,21,36,0,33.25,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,African American (popg),4.04e-10,12.31,21,44,0,31.02,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Hispanics (popg),4.04e-10,14.41,21,27,0,37.33,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,HIV Infections (dsyn),8.15e-10,8.83,21,18,0,33.43,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Glomerular Filtration Rate (ortf),4.09e-10,14.86,21,15,0,25.71,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,offender (popg),9.12e-08,11.86,21,11,0,16.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Participant (humn),4.04e-10,13.51,21,33,0,34.36,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Outpatients (podg),4.06e-10,12.61,21,17,0,30.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Liver diseases (dsyn),4.04e-10,12.61,21,18,0,33.43,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Peripheral Vascular Diseases (dsyn),1.87e-07,16.07,21,9,0,12.86,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Cancer Patient (podg),4.04e-10,7.78,21,85,0,26.19,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Myocardial Ischemia (dsyn),1.12e-08,10.92,21,13,0,21.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Epilepsy (dsyn),4.04e-10,11.57,21,61,0,28.23,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Racial group (popg),4.15e-10,14.0,21,15,0,25.71,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Research Personnel (humn),8.39e-10,8.36,21,19,0,36.19,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),4.04e-10,13.81,21,34,0,33.97,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,inpatient (podg),4.04e-10,13.98,21,152,0,23.9,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Metabolic syndrome (dsyn),6.03e-07,18.01,21,8,0,11.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,cohort (popg),4.04e-10,13.56,21,21,0,42.0,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Atrial Fibrillation (patf),4.12e-10,14.41,21,15,0,25.71,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Young adult (aggp),4.04e-10,9.23,21,89,0,25.96,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Households (humn),4.04e-10,13.19,21,25,0,38.64,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Caucasoid Race (popg),4.04e-10,11.65,21,42,0,31.5,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,General Population (popg),4.04e-10,13.88,21,158,0,23.79,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),4.04e-10,11.18,21,58,0,28.6,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),COEXISTS_WITH,Pregnancy (orgf),4.04e-10,10.14,21,49,0,30.0,9.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pneumonia (dsyn),4.04e-10,10.66,21,29,0,36.21,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Anemia (dsyn),4.04e-10,13.83,21,21,0,42.0,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Age (orga),4.04e-10,14.59,21,125,0,24.53,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Systemic Scleroderma (dsyn),4.04e-10,11.42,21,23,0,40.17,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Offspring (humn),4.04e-10,9.31,21,25,0,38.64,1.0
adiposity (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,538.53,19,23,0,34.7,8.0
adiposity (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.67e-22,537.98,19,57,0,25.33,8.0
adiposity (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,546.44,19,9,0,13.26,8.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,11.54,149,20,0,22.68,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,8.72,149,65,0,93.36,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,11.04,149,16,0,17.72,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,11.3,149,13,0,14.13,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,12.28,149,16,0,17.72,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,17.69,149,8,0,8.43,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,11.16,149,23,0,26.55,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,12.06,149,22,0,25.25,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,11.99,149,13,0,14.13,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,13.98,149,15,0,16.51,1.0
Hypertriglyceridemia (fndg),ISA,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.61e-07,28.33,6,62,0,6.58,5.0
Hypertriglyceridemia (fndg),ISA,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.61e-07,38.93,6,17,0,8.12,5.0
Hypertriglyceridemia (fndg),ISA,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.61e-07,30.62,6,19,0,7.89,5.0
Leptin (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),2.35e-06,56.32,4,5,0,7.2,3.0
Triglycerides (bacs),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),1.8e-06,5.79,10,2,0,2.4,3.0
insulin sensitivity (patf),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.81e-08,60.64,6,16,0,8.25,9.0
insulin sensitivity (patf),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.41e-07,65.81,6,9,0,10.0,9.0
insulin sensitivity (patf),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.2e-07,58.19,6,31,0,7.16,9.0
Metabolic syndrome (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),4.86e-16,73.24,10,25,0,14.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,71.04,10,13,0,17.69,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),4.86e-16,75.5,10,32,0,13.12,1.0
High Density Lipoprotein Cholesterol (bacs),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),2.54e-06,27.09,5,2,0,2.8,3.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.78e-10,70.31,7,33,0,8.48,1.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,70.86,7,16,0,10.06,9.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.93e-11,70.66,7,71,0,7.69,5.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.93e-11,84.5,7,35,0,8.4,9.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.93e-11,70.59,7,110,0,7.45,9.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.37e-09,69.92,7,37,0,8.32,1.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Residual Tumor (neop),7.56e-07,5.53,59,15,0,18.81,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Anastomosis (acab),9.53e-14,5.75,59,30,0,45.25,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"[M]Squamous cell carcinoma, metastatic NOS (neop)",6.02e-14,4.21,59,52,0,97.83,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Rhabdomyosarcoma (neop),7.71e-07,4.04,59,23,0,31.97,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant Squamous Cell Neoplasm (neop),1.19e-13,3.85,59,52,0,97.83,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Adenoid Cystic Carcinoma (neop),2.85e-13,5.81,59,28,0,41.29,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Fracture with displacement (inpo),1.44e-10,4.31,59,32,0,49.36,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),6e-14,3.29,59,526,0,65.62,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,sarcoma (neop),6.01e-14,4.37,59,54,0,103.42,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Secondary malignant neoplasm of lymph node (neop),8.54e-14,3.71,59,58,0,115.02,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"[X]Malignant melanoma of skin, unspecified (neop)",3.04e-09,4.31,59,28,0,41.29,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma of skin (neop),6e-14,6.3,59,43,0,74.34,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,melanoma (neop),6e-14,4.5,59,85,0,99.95,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Merkel cell carcinoma (neop),1.99e-12,5.6,59,27,0,39.36,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Neoplasm Metastasis (neop),1.85e-06,3.83,59,24,0,33.76,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Necrotizing fasciitis (dsyn),6e-14,6.62,59,35,0,55.76,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Wounds and Injuries (inpo),1.61e-07,3.18,59,47,0,84.44,2.0
Body mass index (clna),PREDISPOSES,Dementia (mobd),PROCESS_OF,cohort (popg),4.2e-09,91.4,7,38,0,8.29,1.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),1.21e-08,60.5,9,29,0,11.79,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),7.23e-07,60.25,9,26,0,12.12,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),ISA,Medical Imaging (diap),2.27e-06,58.59,9,318,0,9.25,5.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),3.81e-14,63.73,9,129,0,9.63,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),ISA,Diagnosis (hlca),5e-12,59.36,9,112,0,9.72,5.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),1.32e-08,61.48,9,21,0,12.86,16.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),1.5e-09,64.92,6,33,0,7.09,1.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,65.47,6,16,0,8.25,9.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.24e-09,65.27,6,71,0,6.51,5.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.24e-09,79.11,6,35,0,7.03,21.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.24e-09,65.19,6,110,0,6.33,21.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),2.59e-09,64.53,6,37,0,6.97,1.0
Interleukin-6 (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.63e-06,62.57,4,5,0,7.2,3.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.7e-10,76.72,7,33,0,8.48,1.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,77.27,7,16,0,10.06,9.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.12e-11,77.07,7,71,0,7.69,5.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.12e-11,90.91,7,35,0,8.4,9.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.12e-11,76.99,7,110,0,7.45,9.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.37e-09,76.33,7,37,0,8.32,1.0
Adipose tissue (tisu),LOCATION_OF,"TNF protein, human|TNF (aapp)",PART_OF,Recombinants (orgm),4.66e-10,25.48,9,2,0,2.44,2.0
Overweight (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.44e-07,27.96,6,18,0,8.0,1.0
Birth Weight (orga),ISA,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,66.07,11,22,0,16.5,5.0
Visceral Fat (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,141.26,9,16,0,14.06,7.0
Visceral Fat (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,146.43,9,9,0,18.0,7.0
Visceral Fat (tisu),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,138.81,9,31,0,11.61,7.0
Exercise (dora),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.6e-08,38.22,8,16,0,12.0,4.0
Exercise (dora),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,43.38,8,9,0,15.11,4.0
Exercise (dora),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,35.77,8,31,0,10.06,4.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Stable Disease (fndg),5.61e-15,6.98,29,47,0,46.89,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Senile Plaques (acab),6.08e-07,5.33,29,49,0,46.16,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Pre-existing disease (sosy),6.95e-15,9.16,29,28,0,55.03,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,"Stenosis, unspecified (patf)",9.33e-14,5.39,29,90,0,38.34,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Metal stent (medd),4.43e-06,6.96,29,16,0,24.83,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Drug eluting stent (medd),2.79e-07,7.76,29,16,0,24.83,2.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),3.94e-06,74.3,4,9,0,5.78,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.35e-06,73.36,4,194,0,4.08,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.35e-06,72.08,4,17,0,4.94,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.35e-06,73.35,4,29,0,4.55,11.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.35e-06,75.54,4,14,0,5.14,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),2.42e-06,71.34,4,12,0,5.33,5.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.35e-06,70.16,4,48,0,4.33,11.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.35e-06,73.55,4,29,0,4.55,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.35e-06,70.6,4,98,0,4.16,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.36e-06,69.26,4,24,0,4.67,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.53e-06,75.68,4,10,0,5.6,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.37e-06,68.03,4,37,0,4.43,7.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.36e-06,69.84,4,20,0,4.8,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.35e-06,71.49,4,94,0,4.17,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),3.7e-06,77.28,4,8,0,6.0,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),1.35e-06,74.15,4,19,0,4.84,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.35e-06,71.31,4,21,0,4.76,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.36e-06,76.49,4,12,0,5.33,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.36e-06,84.21,4,10,0,5.6,21.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.44e-06,76.79,4,10,0,5.6,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.35e-06,71.11,4,21,0,4.76,21.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.35e-06,72.72,4,21,0,4.76,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.35e-06,70.85,4,32,0,4.5,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.39e-06,78.2,4,10,0,5.6,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.35e-06,77.17,4,39,0,4.41,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.35e-06,81.15,4,44,0,4.36,11.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.35e-06,74.03,4,113,0,4.14,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),4.1e-06,71.55,4,11,0,5.45,11.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),5.53e-06,71.28,4,11,0,5.45,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),1.91e-06,71.74,4,12,0,5.33,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.35e-06,69.63,4,25,0,4.64,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.35e-06,75.31,4,87,0,4.18,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.35e-06,70.3,4,33,0,4.48,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.35e-06,73.03,4,41,0,4.39,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.35e-06,73.2,4,21,0,4.76,1.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.35e-06,70.87,4,21,0,4.76,9.0
Hyperinsulinism (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.35e-06,71.81,4,1021,0,4.02,11.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.71e-11,472.83,10,25,0,14.0,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.74e-10,476.73,10,15,0,16.67,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),1.87e-20,482.11,10,24,0,14.17,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),7.43e-21,472.74,10,46,0,12.17,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),PROCESS_OF,General Population (popg),6.44e-10,472.31,10,24,0,14.17,1.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.09e-10,474.16,10,18,0,15.56,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),2.11e-17,470.89,10,73,0,11.37,5.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,471.48,10,24,0,14.17,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",9.04e-19,472.8,10,41,0,12.44,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),7.75e-10,473.57,10,19,0,15.26,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.88e-15,474.46,10,26,0,13.85,8.0
Adiponectin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",1.74e-06,27.3,5,79,0,5.32,1.0
Adiponectin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),5.16e-06,27.26,5,29,0,5.86,1.0
Supplementation (topp),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.83e-08,89.62,5,16,0,6.56,9.0
Supplementation (topp),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.51e-07,94.79,5,9,0,7.78,9.0
Supplementation (topp),PREVENTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.3e-07,87.18,5,31,0,5.81,21.0
Body fat percentage (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.98e-07,123.3,4,18,0,4.89,1.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),6.89e-09,48.02,6,33,0,7.09,1.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.44e-06,48.57,6,16,0,8.25,9.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),6.63e-09,48.37,6,71,0,6.51,5.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.63e-09,62.21,6,35,0,7.03,9.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.63e-09,48.3,6,110,0,6.33,9.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),7.98e-09,47.63,6,37,0,6.97,1.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),COEXISTS_WITH,Diabetic (fndg),3.13e-08,77.28,6,28,0,7.29,9.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),PROCESS_OF,cohort (popg),1.31e-06,80.06,6,12,0,9.0,1.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),COEXISTS_WITH,Ischemic stroke (dsyn),2.37e-08,83.03,6,12,0,9.0,9.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),3.46e-06,81.24,6,10,0,9.6,9.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),PROCESS_OF,Hospitalized Patients (podg),4.69e-10,80.2,6,62,0,6.58,1.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),PROCESS_OF,Critically ill children (podg),4.69e-10,84.34,6,30,0,7.2,1.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),COEXISTS_WITH,Traumatic Brain Injury (inpo),6.03e-07,89.44,6,8,0,10.5,9.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),PROCESS_OF,inpatient (podg),4.69e-10,79.06,6,36,0,7.0,1.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.76e-10,79.01,6,25,0,7.44,9.0
Insulin Resistance (patf),COEXISTS_WITH,Hyperglycemia (dsyn),COEXISTS_WITH,Critical Illness (dsyn),4.69e-10,85.28,6,37,0,6.97,9.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.72e-07,114.13,4,22,0,4.73,9.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),2.72e-07,113.56,4,17,0,4.94,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),2.85e-07,109.62,4,27,0,4.59,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),2.86e-07,112.58,4,15,0,5.07,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),2.72e-07,110.78,4,24,0,4.67,9.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),2.72e-07,110.4,4,34,0,4.47,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (popg),2.72e-07,111.82,4,40,0,4.4,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.73e-07,118.55,4,12,0,5.33,9.0
Diet (food),CAUSES,Hyperglycemia (dsyn),COEXISTS_WITH,Diabetic (fndg),4.87e-08,80.4,5,28,0,5.89,9.0
Diet (food),CAUSES,Hyperglycemia (dsyn),PROCESS_OF,cohort (popg),1.33e-06,83.18,5,12,0,7.08,1.0
Diet (food),CAUSES,Hyperglycemia (dsyn),COEXISTS_WITH,Ischemic stroke (dsyn),4.12e-08,86.16,5,12,0,7.08,9.0
Diet (food),CAUSES,Hyperglycemia (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),3.48e-06,84.36,5,10,0,7.5,9.0
Diet (food),CAUSES,Hyperglycemia (dsyn),PROCESS_OF,Hospitalized Patients (podg),1.79e-08,83.32,5,62,0,5.4,1.0
Diet (food),CAUSES,Hyperglycemia (dsyn),PROCESS_OF,Critically ill children (podg),1.79e-08,87.47,5,30,0,5.83,1.0
Diet (food),CAUSES,Hyperglycemia (dsyn),COEXISTS_WITH,Traumatic Brain Injury (inpo),6.21e-07,92.56,5,8,0,8.12,9.0
Diet (food),CAUSES,Hyperglycemia (dsyn),PROCESS_OF,inpatient (podg),1.79e-08,82.18,5,36,0,5.69,1.0
Diet (food),CAUSES,Hyperglycemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.79e-08,82.14,5,25,0,6.0,11.0
Diet (food),CAUSES,Hyperglycemia (dsyn),COEXISTS_WITH,Critical Illness (dsyn),1.79e-08,88.4,5,37,0,5.68,9.0
Waist circumference (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),7.03e-18,177.04,9,136,0,9.6,1.0
Waist circumference (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),7.03e-18,176.17,9,188,0,9.43,1.0
Waist circumference (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (popg),2.53e-06,177.06,9,20,0,13.05,1.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.59e-10,101.17,20,33,0,32.12,1.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,101.72,20,16,0,28.8,9.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,101.52,20,71,0,25.63,5.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,115.37,20,35,0,31.43,21.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),9.84e-36,101.45,20,110,0,23.64,21.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.35e-09,100.79,20,37,0,30.81,1.0
"Fatty Acids, Nonesterified (lipd)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,43.51,8,16,0,12.0,8.0
"Fatty Acids, Nonesterified (lipd)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,48.68,8,9,0,15.11,8.0
"Fatty Acids, Nonesterified (lipd)",ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,41.07,8,31,0,10.06,8.0
Structure of nucleus infundibularis hypothalami (bpoc),PART_OF,Hypothalamic structure (bpoc),LOCATION_OF,Entire paraventricular nucleus (blor),4.59e-16,20.38,34,10,0,12.94,2.0
Lipids (lipd),PART_OF,Adipocytes (cell),PART_OF,Caucasoid Race (popg),2.49e-08,57.78,8,4,0,6.0,3.0
Lipids (lipd),PART_OF,Adipocytes (cell),PART_OF,Stroma (bpoc),1.2e-08,57.8,8,7,0,13.12,3.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),5.98e-06,31.36,5,9,0,7.78,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),3.39e-06,30.41,5,194,0,5.13,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.39e-06,29.14,5,17,0,6.47,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.39e-06,30.41,5,29,0,5.86,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),3.39e-06,32.59,5,14,0,6.79,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),4.45e-06,28.4,5,12,0,7.08,5.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.39e-06,27.22,5,48,0,5.52,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),3.39e-06,30.61,5,29,0,5.86,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.39e-06,27.65,5,98,0,5.26,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),3.39e-06,26.32,5,24,0,6.04,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),3.56e-06,32.73,5,10,0,7.5,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),3.4e-06,25.09,5,37,0,5.68,7.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.39e-06,26.89,5,20,0,6.25,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),3.39e-06,28.54,5,94,0,5.27,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),5.73e-06,34.33,5,8,0,8.12,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),3.39e-06,31.21,5,19,0,6.32,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),3.39e-06,28.36,5,21,0,6.19,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),3.39e-06,33.54,5,12,0,7.08,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.39e-06,41.26,5,10,0,7.5,21.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),3.47e-06,33.84,5,10,0,7.5,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),3.39e-06,28.16,5,21,0,6.19,21.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.39e-06,29.77,5,21,0,6.19,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.39e-06,27.9,5,32,0,5.78,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.42e-06,35.26,5,10,0,7.5,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.39e-06,34.23,5,39,0,5.64,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.39e-06,38.2,5,44,0,5.57,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.39e-06,31.08,5,113,0,5.22,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),6.14e-06,28.61,5,11,0,7.27,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),7.56e-06,28.33,5,11,0,7.27,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),3.95e-06,28.79,5,12,0,7.08,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),3.39e-06,26.69,5,25,0,6.0,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",3.39e-06,32.36,5,87,0,5.29,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.39e-06,27.35,5,33,0,5.76,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),3.39e-06,30.09,5,41,0,5.61,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),3.39e-06,30.26,5,21,0,6.19,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",3.39e-06,27.92,5,21,0,6.19,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.39e-06,28.87,5,1021,0,5.02,11.0
Neuropeptides (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",8.92e-10,49.43,9,79,0,10.03,1.0
Neuropeptides (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.42e-06,49.38,9,29,0,11.79,1.0
Insulin Resistance (patf),PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),1.57e-19,158.84,13,49,0,16.45,1.0
Subcutaneous Fat (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Head (blor),1.67e-06,100.14,8,6,0,10.5,2.0
Subcutaneous Fat (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Neck (blor),6.63e-07,100.43,8,393,0,8.16,2.0
Subcutaneous Fat (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Slipped Epiphyses (dsyn),3.06e-14,100.06,8,1,0,1.12,2.0
Adipocytes (cell),LOCATION_OF,"TNF protein, human|TNF (aapp)",PART_OF,Recombinants (orgm),7.48e-07,18.68,6,2,0,2.67,2.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,398.06,7,20,0,9.45,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,395.25,7,65,0,7.75,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,397.57,7,16,0,10.06,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,397.83,7,13,0,10.77,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,398.81,7,16,0,10.06,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,404.21,7,8,0,13.12,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,397.69,7,23,0,9.13,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,398.58,7,22,0,9.23,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,398.51,7,13,0,10.77,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,400.51,7,15,0,10.27,1.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),2.59e-10,543.98,49,33,0,55.22,1.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,544.52,49,16,0,21.22,8.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,544.33,49,71,0,82.82,5.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,558.17,49,35,0,60.0,8.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,544.25,49,110,0,70.83,8.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.35e-09,543.59,49,37,0,64.94,1.0
Adipose tissue (tisu),PART_OF,Entire trunk (bpoc),LOCATION_OF,Hemorrhage (fndg),5.95e-07,100.14,4,12,0,5.33,2.0
Adipose tissue (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Elephants (mamm),4.25e-07,98.45,4,140,0,4.11,3.0
Adipose tissue (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Aorta (bpoc),4.27e-07,95.85,4,35,0,4.46,3.0
Assessment procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.48e-07,90.23,4,23,0,4.7,4.0
Assessment procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),5.47e-07,89.68,4,57,0,4.28,4.0
Assessment procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),8.38e-07,98.14,4,9,0,5.78,4.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),4.3e-06,289.43,3,9,0,4.0,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.71e-06,288.49,3,194,0,3.05,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.71e-06,287.22,3,17,0,3.53,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.71e-06,288.48,3,29,0,3.31,11.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.71e-06,290.67,3,14,0,3.64,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),2.78e-06,286.47,3,12,0,3.75,5.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.71e-06,285.29,3,48,0,3.19,11.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.71e-06,288.68,3,29,0,3.31,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.71e-06,285.73,3,98,0,3.09,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.71e-06,284.39,3,24,0,3.38,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.89e-06,290.81,3,10,0,3.9,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.72e-06,283.16,3,37,0,3.24,7.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.72e-06,284.97,3,20,0,3.45,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.71e-06,286.62,3,94,0,3.1,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),4.05e-06,292.41,3,8,0,4.12,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),1.71e-06,289.29,3,19,0,3.47,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.71e-06,286.44,3,21,0,3.43,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.71e-06,291.62,3,12,0,3.75,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.71e-06,299.34,3,10,0,3.9,21.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.79e-06,291.92,3,10,0,3.9,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.71e-06,286.24,3,21,0,3.43,21.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.71e-06,287.85,3,21,0,3.43,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.71e-06,285.98,3,32,0,3.28,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.75e-06,293.33,3,10,0,3.9,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.71e-06,292.3,3,39,0,3.23,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.71e-06,296.28,3,44,0,3.2,11.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.71e-06,289.16,3,113,0,3.08,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),4.46e-06,286.68,3,11,0,3.82,11.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),5.89e-06,286.41,3,11,0,3.82,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),2.27e-06,286.87,3,12,0,3.75,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.71e-06,284.77,3,25,0,3.36,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.71e-06,290.44,3,87,0,3.1,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.71e-06,285.43,3,33,0,3.27,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.71e-06,288.17,3,41,0,3.22,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.71e-06,288.33,3,21,0,3.43,1.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.71e-06,286.0,3,21,0,3.43,9.0
Gonadal Steroid Hormones (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.71e-06,286.94,3,1021,0,3.01,11.0
Sedentary (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.2e-07,19.16,7,18,0,9.72,1.0
Atherosclerosis (dsyn),PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),7.34e-10,72.06,6,49,0,6.73,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,19.61,25,20,0,36.0,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,16.79,25,65,0,34.62,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,19.12,25,16,0,26.24,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,19.37,25,13,0,19.76,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,20.35,25,16,0,26.24,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,25.76,25,8,0,10.56,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,19.24,25,23,0,44.16,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,20.13,25,22,0,41.36,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,20.06,25,13,0,19.76,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,22.06,25,15,0,24.0,1.0
Fat-free mass (fndg),PROCESS_OF,"Infant, Premature (humn)",LOCATION_OF,"Ductus Arteriosus, Patent (cgab)",1.95e-08,252.69,4,50,0,4.32,1.0
Fat-free mass (fndg),PROCESS_OF,"Infant, Premature (humn)",LOCATION_OF,Nitric Oxide (inch),1.95e-08,254.53,4,23,0,4.7,1.0
Cerebrospinal Fluid (bdsu),LOCATION_OF,Insulin (horm),TREATS,Hospitalized Patients (podg),3.85e-06,75.69,4,11,0,5.45,2.0
Cerebrospinal Fluid (bdsu),LOCATION_OF,Insulin (horm),TREATS,Hyperglycemia (dsyn),1.1e-06,73.47,4,57,0,4.28,2.0
Life Style (socb),ISA,Behavior (inbe),PROCESS_OF,network (humn),2.21e-06,11.48,47,4,0,4.34,1.0
Fatty Acid-Binding Proteins (aapp),PART_OF,Adipocytes (cell),PART_OF,Caucasoid Race (popg),2.49e-08,11.36,21,4,0,4.76,3.0
Fatty Acid-Binding Proteins (aapp),PART_OF,Adipocytes (cell),PART_OF,Stroma (bpoc),1.2e-08,11.39,21,7,0,9.33,3.0
Systolic blood pressure (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.27e-07,19.11,7,18,0,9.72,1.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),1.04e-10,35.71,8,34,0,9.88,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),4.12e-10,36.09,8,21,0,11.05,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),1.04e-10,39.45,8,38,0,9.68,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),1.04e-10,35.02,8,35,0,9.83,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,cohort (popg),1.05e-10,33.95,8,49,0,9.31,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),1.04e-10,39.31,8,25,0,10.56,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),1.34e-06,40.93,8,9,0,15.11,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),5.49e-08,35.85,8,17,0,11.76,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),4.78e-10,34.29,8,33,0,9.94,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),1.87e-10,37.82,8,18,0,11.56,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),2.98e-06,35.97,8,13,0,12.92,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),4.76e-07,36.28,8,14,0,12.57,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),4.77e-07,35.84,8,15,0,12.27,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),8.92e-09,35.28,8,21,0,11.05,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),1.88e-06,40.46,8,9,0,15.11,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (phsu),6.69e-09,37.08,8,16,0,12.0,5.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),2.18e-09,36.56,8,18,0,11.56,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),1.04e-10,35.87,8,67,0,8.96,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),3.47e-06,42.22,8,8,0,16.0,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),8.1e-10,36.17,8,20,0,11.2,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),1.04e-10,44.69,8,17,0,11.76,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),1.05e-09,34.52,8,29,0,10.21,5.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),3.47e-06,42.22,8,8,0,16.0,5.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),1.81e-07,12.48,9,34,0,11.38,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),1.81e-07,12.86,9,21,0,12.86,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),1.81e-07,16.22,9,38,0,11.13,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),1.81e-07,11.79,9,35,0,11.31,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,cohort (popg),1.81e-07,10.72,9,49,0,10.65,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),1.81e-07,16.08,9,25,0,12.24,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),1.52e-06,17.71,9,9,0,18.0,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),2.36e-07,12.63,9,17,0,13.76,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),1.81e-07,11.06,9,33,0,11.45,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),1.81e-07,14.6,9,18,0,13.5,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),3.16e-06,12.74,9,13,0,15.23,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),6.57e-07,13.05,9,14,0,14.79,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),6.58e-07,12.62,9,15,0,14.4,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),1.9e-07,12.05,9,21,0,12.86,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),2.06e-06,17.23,9,9,0,18.0,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (phsu),1.88e-07,13.85,9,16,0,14.06,5.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),1.83e-07,13.33,9,18,0,13.5,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),1.81e-07,12.65,9,67,0,10.21,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),3.65e-06,18.99,9,8,0,15.11,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),1.82e-07,12.94,9,20,0,13.05,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),1.81e-07,21.46,9,17,0,13.76,4.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),1.82e-07,11.29,9,29,0,11.79,5.0
X-Ray Computed Tomography (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),3.65e-06,18.99,9,8,0,15.11,5.0
Blood specimen (bdsu),LOCATION_OF,Insulin (horm),TREATS,Hospitalized Patients (podg),2.75e-06,67.12,9,11,0,16.36,2.0
Blood specimen (bdsu),LOCATION_OF,Insulin (horm),TREATS,Hyperglycemia (dsyn),2.37e-14,64.91,9,57,0,10.42,2.0
Insulin Resistance (patf),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),4.11e-06,189.91,3,98,0,3.09,1.0
Insulin Resistance (patf),PROCESS_OF,African American (popg),ISA,Racial group (popg),4.11e-06,190.84,3,324,0,3.03,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,48.49,13,20,0,21.45,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,45.67,13,65,0,15.6,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,48.0,13,16,0,23.56,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,48.25,13,13,0,26.0,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,49.23,13,16,0,23.56,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,54.64,13,8,0,12.92,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,48.11,13,23,0,20.35,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,49.01,13,22,0,20.68,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,48.94,13,13,0,26.0,1.0
Overweight (sosy),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,50.94,13,15,0,24.27,1.0
Caudal (blor),LOCATION_OF,Brain Stem (bpoc),LOCATION_OF,Hernia (anab),1.18e-06,16.87,12,15,0,21.6,2.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,38.48,40,9,0,11.03,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.14e-52,37.54,40,194,0,48.25,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,36.26,40,17,0,24.22,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,37.53,40,29,0,50.02,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,39.71,40,14,0,18.9,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,35.52,40,12,0,15.6,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,34.34,40,48,0,73.33,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.51e-19,37.73,40,29,0,50.02,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.75e-50,34.78,40,98,0,56.33,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,39.85,40,10,0,12.5,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,32.21,40,37,0,71.23,7.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,34.01,40,20,0,30.0,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.21e-52,35.67,40,94,0,57.02,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,41.46,40,8,0,9.6,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),3.13e-13,38.33,40,19,0,28.02,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,35.49,40,21,0,32.02,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,40.67,40,12,0,15.6,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,48.38,40,10,0,12.5,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,40.97,40,10,0,12.5,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,35.29,40,21,0,32.02,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,36.9,40,21,0,32.02,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,35.02,40,32,0,57.6,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,42.38,40,10,0,12.5,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,41.35,40,39,0,77.02,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,45.33,40,44,0,76.36,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.14e-52,38.2,40,113,0,54.16,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,35.73,40,11,0,14.03,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,35.45,40,11,0,14.03,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,35.92,40,12,0,15.6,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,33.81,40,25,0,40.62,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.14e-52,39.49,40,87,0,58.39,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,34.47,40,33,0,60.22,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),9.09e-27,37.21,40,41,0,79.02,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,37.38,40,21,0,32.02,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,35.04,40,21,0,32.02,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.14e-52,35.99,40,1021,0,41.57,11.0
Metabolic syndrome (dsyn),PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),5.56e-14,95.03,8,49,0,9.31,1.0
Physical activity (dora),ISA,Behavior (inbe),PROCESS_OF,network (humn),2.21e-06,15.56,20,4,0,4.8,1.0
insulin sensitivity (patf),AFFECTS,Aging (orgf),PROCESS_OF,Population Group (popg),1.97e-10,239.41,5,138,0,5.18,1.0
insulin sensitivity (patf),AFFECTS,Aging (orgf),PROCESS_OF,cohort (popg),1.97e-10,236.99,5,47,0,5.53,1.0
insulin sensitivity (patf),AFFECTS,Aging (orgf),PROCESS_OF,Actuary (humn),1.98e-10,241.01,5,20,0,6.25,1.0
insulin sensitivity (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.33e-09,61.11,6,18,0,8.0,1.0
Insulin (horm),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,30.65,12,16,0,21.0,4.0
Insulin (horm),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,35.81,12,9,0,15.75,4.0
Insulin (horm),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,28.2,12,31,0,16.65,4.0
Adiponectin (aapp),COEXISTS_WITH,Insulin (horm),TREATS,Hospitalized Patients (podg),2.75e-06,117.89,5,11,0,7.27,4.0
Adiponectin (aapp),COEXISTS_WITH,Insulin (horm),TREATS,Hyperglycemia (dsyn),3.81e-09,115.68,5,57,0,5.44,4.0
Overweight (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,34.31,28,18,0,29.57,1.0
Adipocytes (cell),LOCATION_OF,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,51.44,22,2,0,2.18,2.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,17.82,42,20,0,29.52,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,15.0,42,65,0,69.14,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,17.33,42,16,0,22.1,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,17.58,42,13,0,17.02,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,18.56,42,16,0,22.1,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,23.97,42,8,0,9.52,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,17.45,42,23,0,35.6,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,18.34,42,22,0,33.52,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,18.27,42,13,0,17.02,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,20.27,42,15,0,20.36,1.0
PROTEIN KINASE (aapp),AFFECTS,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),9.47e-09,321.59,4,5,0,7.2,3.0
Leptin|LEP (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,79.34,29,5,0,5.86,3.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hilum (bpoc),2.1e-12,125.31,9,56,0,10.45,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Neoplasm Metastasis (neop),9.72e-17,126.55,9,48,0,10.69,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Tumor Burden (diap),3.95e-15,128.44,9,28,0,11.89,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Primary Neoplasm (neop),1.07e-10,125.88,9,35,0,11.31,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Toxic effect (inpo),9.52e-17,124.92,9,145,0,9.56,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Decompensation (fndg),9.52e-17,127.42,9,224,0,9.36,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hydrothorax (dsyn),7.51e-13,125.24,9,61,0,10.33,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Medical Imaging (diap),6.93e-09,123.59,9,3,0,4.0,2.0
SCD (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hepatic Veno-Occlusive Disease (dsyn),4.19e-07,126.44,9,19,0,13.26,2.0
Adipocytes (cell),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),6.38e-12,28.19,10,5,0,7.5,3.0
LIPOPROTEIN LIPASE|LPL (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,20.21,14,5,0,6.79,3.0
Leptin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",5.93e-07,34.98,5,79,0,5.32,1.0
Leptin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),4.01e-06,34.94,5,29,0,5.86,1.0
Triglycerides (bacs),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,27.96,12,5,0,7.08,3.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.89e-07,29.13,6,18,0,8.0,1.0
adiposity (orga),ASSOCIATED_WITH,"Puberty, Precocious (dsyn)",PROCESS_OF,Girls (popg),3.58e-06,562.76,5,3,0,4.8,1.0
Body mass index (clna),PREDISPOSES,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.22e-07,86.68,4,62,0,4.26,21.0
Body mass index (clna),PREDISPOSES,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.22e-07,97.28,4,17,0,4.94,21.0
Body mass index (clna),PREDISPOSES,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.22e-07,88.97,4,19,0,4.84,9.0
Adiponectin (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,44.63,19,5,0,6.32,3.0
Assessment procedure (hlca),TREATS,Participant (humn),USES,Medicare (rnlw),7.39e-08,12.7,10,18,0,15.56,4.0
"TNF protein, human|TNF (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.83e-07,30.14,6,16,0,8.25,8.0
"TNF protein, human|TNF (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.08e-06,35.31,6,9,0,10.0,8.0
"TNF protein, human|TNF (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.55e-07,27.69,6,31,0,7.16,8.0
Abdominal obesity (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),4.35e-06,49.29,4,33,0,4.48,1.0
Abdominal obesity (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),8.79e-06,49.83,4,16,0,5.0,9.0
Abdominal obesity (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.35e-06,49.63,4,71,0,4.23,5.0
Abdominal obesity (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.35e-06,63.48,4,35,0,4.46,9.0
Abdominal obesity (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.35e-06,49.56,4,110,0,4.15,9.0
Abdominal obesity (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),4.36e-06,48.9,4,37,0,4.43,1.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),5.48e-07,88.96,4,33,0,4.48,1.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.98e-06,89.51,4,16,0,5.0,9.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.47e-07,89.31,4,71,0,4.23,5.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.47e-07,103.15,4,35,0,4.46,21.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.47e-07,89.24,4,110,0,4.15,21.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),5.49e-07,88.57,4,37,0,4.43,1.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),1.38e-07,134.79,4,33,0,4.48,1.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.57e-06,135.34,4,16,0,5.0,8.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.38e-07,135.14,4,71,0,4.23,5.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.38e-07,148.98,4,35,0,4.46,8.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-07,135.07,4,110,0,4.15,8.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.39e-07,134.4,4,37,0,4.43,1.0
Skeletal muscle structure (bpoc),LOCATION_OF,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,17.48,13,16,0,23.56,2.0
Skeletal muscle structure (bpoc),LOCATION_OF,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,22.65,13,9,0,15.23,2.0
Skeletal muscle structure (bpoc),LOCATION_OF,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,15.03,13,31,0,18.45,2.0
PPAR gamma (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),6.03e-11,34.95,8,5,0,8.12,3.0
"RNA, Messenger (bacs)",PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),2.51e-08,72.2,5,5,0,10.0,3.0
Insulin Resistance (patf),PROCESS_OF,Asians (popg),ISA,Population Group (popg),3.84e-09,115.63,5,29,0,5.86,1.0
Insulin Resistance (patf),PROCESS_OF,Asians (popg),ISA,Ethnic group (popg),3.81e-09,114.22,5,124,0,5.2,1.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,Cholesterol (bacs),PART_OF,Membrane (celc),1.48e-08,39.31,6,5,0,9.17,3.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),1.62e-08,82.78,5,33,0,5.76,1.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.45e-06,83.33,5,16,0,6.56,9.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.59e-08,83.13,5,71,0,5.35,5.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.59e-08,96.97,5,35,0,5.71,21.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.59e-08,83.06,5,110,0,5.23,21.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.73e-08,82.39,5,37,0,5.68,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),1.2e-06,83.94,4,16,0,5.0,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),7.02e-07,94.15,4,26,0,4.62,8.0
Insulin Resistance (patf),PROCESS_OF,Hispanics (popg),ISA,Ethnic group (popg),1.49e-10,95.86,6,226,0,6.16,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.22e-06,75.15,4,22,0,4.73,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.22e-06,74.58,4,17,0,4.94,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (popg),1.23e-06,70.65,4,27,0,4.59,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.23e-06,73.61,4,15,0,5.07,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.22e-06,71.81,4,24,0,4.67,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.22e-06,71.43,4,34,0,4.47,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (popg),1.22e-06,72.85,4,40,0,4.4,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-06,79.58,4,12,0,5.33,8.0
risk factors (qnco),ISA,Risk (qlco),ISA,Probability (qnco),1.77e-08,10.27,24,42,0,37.71,5.0
risk factors (qnco),ISA,Risk (qlco),ISA,contextual factors (ftcn),2.06e-19,10.76,24,104,0,29.54,5.0
risk factors (qnco),ISA,Risk (qlco),ISA,Socioeconomic Factors (grpa),3.11e-07,10.75,24,26,0,46.15,5.0
risk factors (qnco),ISA,Risk (qlco),ISA,Techniques (ftcn),2.06e-19,10.59,24,143,0,28.03,5.0
PPAR gamma (aapp),PART_OF,Adipocytes (cell),PART_OF,Caucasoid Race (popg),1.87e-07,46.95,5,4,0,7.2,3.0
PPAR gamma (aapp),PART_OF,Adipocytes (cell),PART_OF,Stroma (bpoc),1.74e-07,46.98,5,7,0,8.57,3.0
neuropeptide Y|NPY (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",8.92e-10,84.25,10,79,0,11.27,1.0
neuropeptide Y|NPY (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.42e-06,84.21,10,29,0,13.45,1.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),1.34e-08,150.36,5,29,0,5.86,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),7.24e-07,150.11,5,26,0,5.96,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),ISA,Medical Imaging (diap),2.27e-06,148.45,5,318,0,5.08,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),1.22e-09,153.59,5,129,0,5.19,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),ISA,Diagnosis (hlca),1.23e-09,149.22,5,112,0,5.22,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),1.44e-08,151.34,5,21,0,6.19,2.0
Weight steady (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),4.11e-06,192.39,3,18,0,3.5,1.0
Exercise (dora),CAUSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.79e-06,38.25,5,12,0,7.08,1.0
Exercise (dora),CAUSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.99e-07,35.61,5,24,0,6.04,5.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,70.05,32,9,0,11.53,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),2.71e-51,69.1,32,194,0,37.28,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,67.83,32,17,0,26.03,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,69.1,32,29,0,55.28,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,71.28,32,14,0,20.12,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,67.09,32,12,0,16.5,5.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,65.91,32,48,0,53.33,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.51e-19,69.3,32,29,0,55.28,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.01e-50,66.35,32,98,0,42.45,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,65.01,32,24,0,42.0,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,71.42,32,10,0,13.12,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,63.78,32,37,0,59.68,7.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,65.58,32,20,0,32.5,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),2.72e-51,67.23,32,94,0,42.89,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,73.03,32,8,0,10.0,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),3.13e-13,69.9,32,19,0,30.28,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,67.05,32,21,0,34.78,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,72.23,32,12,0,16.5,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,79.95,32,10,0,13.12,21.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,72.54,32,10,0,13.12,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,66.86,32,21,0,34.78,21.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,68.46,32,21,0,34.78,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,66.59,32,32,0,64.0,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,73.95,32,10,0,13.12,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,72.92,32,39,0,58.26,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,76.89,32,44,0,55.27,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.71e-51,69.77,32,113,0,41.06,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,67.3,32,11,0,14.78,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,67.02,32,11,0,14.78,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,67.48,32,12,0,16.5,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,65.38,32,25,0,44.53,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",2.71e-51,71.05,32,87,0,43.77,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,66.04,32,33,0,63.03,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),9.09e-27,68.78,32,41,0,56.98,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,68.95,32,21,0,34.78,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,66.61,32,21,0,34.78,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.71e-51,67.56,32,1021,0,33.0,11.0
Adipocytes (cell),PART_OF,Bone Marrow (bpoc),LOCATION_OF,Micrometastasis (fndg),1.31e-06,62.13,22,41,0,33.8,2.0
Adipocytes (cell),PART_OF,Bone Marrow (bpoc),LOCATION_OF,Infiltration (patf),3.13e-19,62.1,22,127,0,25.81,2.0
Adipocytes (cell),PART_OF,Bone Marrow (bpoc),LOCATION_OF,Histiocytosis haematophagic (dsyn),5.48e-08,64.65,22,17,0,30.14,2.0
Dual-Energy X-Ray Absorptiometry (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,63.31,8,18,0,11.56,6.0
Adiponectin (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,49.84,8,16,0,12.0,9.0
Adiponectin (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,55.01,8,9,0,15.11,9.0
Adiponectin (aapp),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,47.39,8,31,0,10.06,21.0
Lipids (lipd),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.21e-08,37.47,6,16,0,8.25,8.0
Lipids (lipd),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.75e-07,42.63,6,9,0,10.0,8.0
Lipids (lipd),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.54e-07,35.02,6,31,0,7.16,8.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,99.57,13,9,0,15.23,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),9.71e-23,98.63,13,194,0,13.87,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,97.36,13,17,0,22.94,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,98.62,13,29,0,18.83,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,100.81,13,14,0,25.07,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,96.61,13,12,0,23.08,5.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.95e-22,95.43,13,48,0,16.52,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.51e-19,98.82,13,29,0,18.83,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.71e-23,95.87,13,98,0,14.72,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,94.53,13,24,0,20.04,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,100.95,13,10,0,17.69,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,93.3,13,37,0,17.57,7.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,95.11,13,20,0,21.45,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),9.71e-23,96.76,13,94,0,14.8,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,102.55,13,8,0,12.92,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),3.13e-13,99.43,13,19,0,21.89,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,96.58,12,20,1,19.2,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,101.76,13,12,0,23.08,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,109.48,13,10,0,17.69,21.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,102.06,13,10,0,17.69,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,96.38,13,21,0,21.05,21.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,97.99,13,21,0,21.05,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,96.12,13,32,0,18.28,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,103.47,13,10,0,17.69,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),9.71e-23,102.44,13,39,0,17.33,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),9.71e-23,106.42,13,44,0,16.84,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",9.71e-23,99.3,13,113,0,14.5,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,96.82,13,11,0,20.31,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,96.55,13,11,0,20.31,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,97.01,13,12,0,23.08,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,94.9,13,25,0,19.76,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",9.71e-23,100.58,13,87,0,14.94,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,95.57,13,33,0,18.12,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),9.71e-23,98.3,13,41,0,17.12,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,98.47,13,21,0,21.05,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,96.14,13,21,0,21.05,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),9.71e-23,97.08,13,1021,0,13.17,11.0
Adiponectin (aapp),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",7.38e-08,74.7,5,16,0,6.56,9.0
Adiponectin (aapp),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.67e-07,79.87,5,9,0,7.78,9.0
Adiponectin (aapp),CAUSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.45e-07,72.26,5,31,0,5.81,11.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,cohort (popg),7.31e-14,486.96,6,77,0,6.47,1.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1e-08,487.3,6,16,0,8.25,1.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.08e-06,486.75,6,12,0,9.0,1.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.35e-10,487.09,6,19,0,7.89,1.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.38e-09,485.87,6,22,0,7.64,8.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),5.76e-08,484.88,6,24,0,7.5,1.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,General Population (popg),7.31e-14,486.59,6,42,0,6.86,1.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),7.31e-14,487.84,6,102,0,6.35,5.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.34e-07,487.43,6,13,0,8.77,8.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),7.31e-14,487.17,6,83,0,6.43,1.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),7.31e-14,489.76,6,250,0,6.14,5.0
adiposity (orga),ASSOCIATED_WITH,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),7.31e-14,486.93,6,194,0,6.19,8.0
Hyperinsulinism (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",9.77e-07,35.63,5,16,0,6.56,9.0
Hyperinsulinism (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.87e-06,40.79,5,9,0,7.78,9.0
Hyperinsulinism (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.05e-06,33.18,5,31,0,5.81,9.0
Adipocytes (cell),PART_OF,Caucasoid Race (popg),ISA,Racial group (popg),1.94e-42,28.07,56,136,0,79.06,3.0
Adipocytes (cell),PART_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),1.23e-33,27.2,56,188,0,72.68,3.0
Adipocytes (cell),PART_OF,Caucasoid Race (popg),ISA,Population Group (popg),2.53e-06,28.09,56,20,0,27.14,3.0
Magnetic Resonance Imaging (diap),METHOD_OF,Magnetic Resonance Spectroscopy (diap),USES,Mandibular right second molar prosthesis (medd),2.68e-07,88.33,8,3,0,4.12,6.0
Magnetic Resonance Imaging (diap),METHOD_OF,Magnetic Resonance Spectroscopy (diap),USES,Protons (elii),7.3e-14,88.39,8,35,0,9.83,6.0
CLOCK gene|CLOCK (gngm),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),9.47e-09,321.59,4,5,0,7.2,3.0
Abdomen (blor),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),3.75e-08,17.19,27,18,0,30.0,2.0
Abdomen (blor),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),2.51e-07,22.47,27,10,0,13.7,2.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),1.89e-08,82.29,5,20,0,6.25,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.05e-08,79.48,5,65,0,5.38,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),USES,Treats (clas),3.93e-07,81.8,5,16,0,6.56,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.11e-06,82.05,5,13,0,6.92,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),USES,Classification (clas),3.02e-08,83.04,5,16,0,6.56,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.49e-06,88.44,5,8,0,8.12,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.81e-08,81.92,5,23,0,6.09,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.79e-08,82.81,5,22,0,6.14,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),9.02e-07,82.74,5,13,0,6.92,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.95e-08,84.74,5,15,0,6.67,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),9.86e-07,22.52,6,18,0,8.0,1.0
Insulin Resistance (patf),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.88e-07,81.28,4,23,0,4.7,21.0
Insulin Resistance (patf),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),7.88e-07,80.72,4,57,0,4.28,11.0
Insulin Resistance (patf),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.08e-06,89.19,4,9,0,5.78,9.0
adiposity (orga),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,405.49,5,16,0,6.56,8.0
adiposity (orga),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.79e-11,415.7,5,26,0,5.96,8.0
Obese build (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.8e-10,139.5,7,23,0,9.13,8.0
Obese build (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),2.89e-13,138.95,7,57,0,7.86,8.0
Obese build (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,147.41,7,9,0,12.44,8.0
Physical activity (dora),CAUSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),3.6e-06,60.04,4,12,0,5.33,1.0
Physical activity (dora),CAUSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),2.61e-06,57.41,4,24,0,4.67,5.0
Skinfold Thickness (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,Survivors (humn),4.77e-07,568.17,3,15,0,3.6,1.0
Skinfold Thickness (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",4.66e-07,564.65,3,60,0,3.15,1.0
Skinfold Thickness (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.66e-07,565.52,3,33,0,3.27,1.0
Skinfold Thickness (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,Singleton (humn),4.66e-07,564.16,3,357,0,3.03,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,156.18,5,9,0,7.78,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.22e-09,155.24,5,194,0,5.13,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.56e-09,153.97,5,17,0,6.47,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.22e-09,155.23,5,29,0,5.86,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.42e-09,157.42,5,14,0,6.79,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,153.22,5,12,0,7.08,5.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.22e-09,152.04,5,48,0,5.52,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.22e-09,155.44,5,29,0,5.86,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.22e-09,152.48,5,98,0,5.26,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),3.55e-09,151.14,5,24,0,6.04,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.77e-07,157.56,5,10,0,7.5,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.34e-08,149.92,5,37,0,5.68,7.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),7.95e-09,151.72,5,20,0,6.25,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.22e-09,153.37,5,94,0,5.27,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,159.16,5,8,0,8.12,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),1.22e-09,156.04,5,19,0,6.32,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.23e-09,153.19,5,21,0,6.19,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),4e-09,158.37,5,12,0,7.08,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.86e-09,166.09,5,10,0,7.5,21.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.3e-08,158.67,5,10,0,7.5,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.24e-09,152.99,5,21,0,6.19,21.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.22e-09,154.6,5,21,0,6.19,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.22e-09,152.73,5,32,0,5.78,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.65e-08,160.09,5,10,0,7.5,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,159.05,5,39,0,5.64,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.22e-09,163.03,5,44,0,5.57,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.22e-09,155.91,5,113,0,5.22,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,153.43,5,11,0,7.27,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,153.16,5,11,0,7.27,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.61e-07,153.62,5,12,0,7.08,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.34e-09,151.52,5,25,0,6.0,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.22e-09,157.19,5,87,0,5.29,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.22e-09,152.18,5,33,0,5.76,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.22e-09,154.92,5,41,0,5.61,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.22e-09,155.08,5,21,0,6.19,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.27e-09,152.75,5,21,0,6.19,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.22e-09,153.7,5,1021,0,5.02,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,78.47,14,9,0,14.79,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),4.72e-23,77.52,14,194,0,15.01,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,76.25,14,17,0,25.53,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,77.52,14,29,0,20.76,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,79.7,14,14,0,28.0,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,75.51,14,12,0,22.29,5.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.45e-22,74.33,14,48,0,18.08,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.51e-19,77.72,14,29,0,20.76,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.72e-23,74.76,14,98,0,16.0,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,73.43,14,24,0,22.17,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,79.84,14,10,0,17.14,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,72.2,14,37,0,19.3,7.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,74.0,14,20,0,23.8,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),4.72e-23,75.65,13,93,1,14.82,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,81.44,14,8,0,12.57,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),3.13e-13,78.32,14,19,0,24.32,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,75.47,14,21,0,23.33,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,80.65,14,12,0,22.29,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,88.37,14,10,0,17.14,21.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,80.96,14,10,0,17.14,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,75.27,14,21,0,23.33,21.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,76.88,14,21,0,23.33,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,75.01,14,32,0,20.12,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,82.37,14,10,0,17.14,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.72e-23,81.34,14,39,0,19.03,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),4.72e-23,85.31,14,44,0,18.45,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.72e-23,78.19,14,113,0,15.73,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,75.72,14,11,0,19.64,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,75.44,14,11,0,19.64,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,75.9,14,12,0,22.29,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,73.8,14,25,0,21.84,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",4.72e-23,79.47,14,87,0,16.25,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,74.46,14,33,0,19.94,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),4.73e-23,77.2,14,41,0,18.78,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,77.37,14,21,0,23.33,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,75.03,14,21,0,23.33,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),4.72e-23,75.98,14,1021,0,14.19,11.0
Organ (bpoc),LOCATION_OF,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.54e-06,68.67,4,16,0,5.0,2.0
Organ (bpoc),LOCATION_OF,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),2.43e-06,73.84,4,9,0,5.78,2.0
Organ (bpoc),LOCATION_OF,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.61e-06,66.22,4,31,0,4.52,2.0
Diabetic (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,18.07,15,18,0,27.5,1.0
Proteome (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.41e-08,82.8,5,5,0,10.0,3.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (popg),2.67e-07,847.39,3,20,0,3.45,1.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),2.49e-07,850.54,3,36,0,3.25,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),2.49e-07,847.17,3,59,0,3.15,5.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.69e-07,846.83,3,23,0,3.39,1.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),6.02e-07,849.83,3,12,0,3.75,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (popg),2.49e-07,847.54,3,72,0,3.12,1.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),2.49e-07,847.0,3,73,0,3.12,5.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (podg),2.49e-07,848.34,3,50,0,3.18,1.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),2.52e-07,850.13,3,15,0,3.6,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),2.49e-07,850.06,3,184,0,3.05,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),2.67e-07,845.6,3,43,0,3.21,1.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (popg),2.49e-07,847.56,3,27,0,3.33,1.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),4.19e-07,851.61,3,11,0,3.82,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),2.49e-07,849.74,3,31,0,3.29,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),2.49e-07,846.9,3,70,0,3.13,1.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),4.88e-07,846.07,3,27,0,3.33,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),2.49e-07,848.05,3,46,0,3.2,5.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),3.37e-07,847.77,3,17,0,3.53,8.0
adiposity (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),6.94e-07,849.67,3,12,0,3.75,8.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.68e-07,25.03,6,23,0,7.57,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.68e-07,24.48,6,57,0,6.63,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),6.59e-07,32.95,6,9,0,10.0,9.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),5.23e-08,256.58,4,13,0,5.23,16.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),5.2e-08,259.51,4,11,0,5.45,7.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),1.98e-08,260.72,4,13,0,5.23,16.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),1.95e-08,256.01,4,27,0,4.59,5.0
Subcutaneous Fat (tisu),PART_OF,Caucasoid Race (popg),ISA,Racial group (popg),2e-08,78.42,5,136,0,5.18,3.0
Subcutaneous Fat (tisu),PART_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),2e-08,77.55,5,188,0,5.13,3.0
Subcutaneous Fat (tisu),PART_OF,Caucasoid Race (popg),ISA,Population Group (popg),2.55e-06,78.44,5,20,0,6.25,3.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,64.02,36,16,0,23.11,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,69.19,36,9,0,11.25,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,61.57,36,31,0,57.69,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,547.75,23,9,0,12.52,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),1.23e-54,546.8,23,194,0,25.73,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,545.53,23,17,0,29.57,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,546.8,23,29,0,41.24,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,548.98,23,14,0,22.52,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,544.79,23,12,0,18.26,5.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,543.61,23,48,0,34.02,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),1.51e-19,547.0,23,29,0,41.24,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.74e-50,544.04,23,98,0,28.4,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,542.71,23,24,0,45.04,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,549.12,23,10,0,14.35,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,541.48,23,37,0,37.3,7.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,543.28,23,20,0,37.39,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),7.9e-54,544.93,23,94,0,28.63,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,550.72,23,8,0,10.78,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),3.13e-13,547.6,23,19,0,34.7,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,544.75,23,21,0,40.17,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,549.93,23,12,0,18.26,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,557.65,23,10,0,14.35,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,550.24,23,10,0,14.35,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,544.55,23,21,0,40.17,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,546.16,23,21,0,40.17,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,544.29,23,32,0,39.53,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,551.65,23,10,0,14.35,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,550.62,23,39,0,36.56,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,554.59,23,44,0,35.02,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.23e-54,547.47,23,113,0,27.68,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,545.0,23,11,0,16.26,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,544.72,23,11,0,16.26,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,545.18,23,12,0,18.26,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,543.08,23,25,0,44.16,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",1.23e-54,548.75,23,87,0,29.08,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,543.74,23,33,0,39.03,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),9.09e-27,546.48,23,41,0,35.9,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,546.65,23,21,0,40.17,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,544.31,23,21,0,40.17,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.23e-54,545.26,23,1021,0,23.52,8.0
Leptin|LEP (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.68e-07,87.73,4,16,0,5.0,7.0
Leptin|LEP (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.56e-06,92.89,4,9,0,5.78,7.0
Leptin|LEP (aapp),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),7.39e-07,85.28,4,31,0,4.52,7.0
Leptin|LEP (aapp),PART_OF,Adipocytes (cell),PART_OF,Caucasoid Race (popg),2.49e-08,43.35,9,4,0,5.78,3.0
Leptin|LEP (aapp),PART_OF,Adipocytes (cell),PART_OF,Stroma (bpoc),1.2e-08,43.38,9,7,0,12.44,3.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),2.19e-07,27.75,6,20,0,7.8,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.21e-07,24.93,6,65,0,6.55,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),USES,Treats (clas),5.93e-07,27.26,6,16,0,8.25,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.31e-06,27.51,6,13,0,8.77,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),USES,Classification (clas),2.3e-07,28.49,6,16,0,8.25,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.69e-06,33.9,6,8,0,10.5,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),2.18e-07,27.38,6,23,0,7.57,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),2.18e-07,28.27,6,22,0,7.64,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.1e-06,28.2,6,13,0,8.77,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.2e-07,30.2,6,15,0,8.4,1.0
Fatty Liver (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,92.78,10,18,0,15.56,1.0
Adipose tissue (tisu),PART_OF,Bone Marrow (bpoc),LOCATION_OF,Micrometastasis (fndg),1.31e-06,46.18,14,41,0,18.78,2.0
Adipose tissue (tisu),PART_OF,Bone Marrow (bpoc),LOCATION_OF,Infiltration (patf),3.28e-19,46.15,14,127,0,15.54,2.0
Adipose tissue (tisu),PART_OF,Bone Marrow (bpoc),LOCATION_OF,Histiocytosis haematophagic (dsyn),5.48e-08,48.7,14,17,0,25.53,2.0
UCP1 (gngm),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,132.47,8,5,0,8.12,3.0
adiposity (orga),ISA,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,525.21,315,22,0,23.54,5.0
Adipose tissue (tisu),PART_OF,Epididymis (bpoc),LOCATION_OF,Localized adiposity (fndg),2.15e-06,42.52,126,2,0,2.03,2.0
Intervention regimes (hlca),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,20.55,11,12,0,21.08,1.0
Intervention regimes (hlca),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,17.91,11,24,0,16.04,4.0
Leptin|LEP (aapp),AUGMENTS,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,150.13,8,5,0,8.12,3.0
Visceral Fat (tisu),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),6.1e-10,175.9,5,5,0,10.0,3.0
adiposity (orga),ASSOCIATED_WITH,HIV Infections (dsyn),PROCESS_OF,cohort (popg),4.66e-07,565.19,3,39,0,3.23,1.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.06e-07,46.36,5,16,0,6.56,9.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.2e-06,51.53,5,9,0,7.78,9.0
Adipocytes (cell),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),5.26e-07,114.81,5,11,0,7.27,2.0
Adipocytes (cell),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.38e-09,109.07,5,194,0,5.13,2.0
Adipocytes (cell),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),4.44e-09,108.3,5,75,0,5.33,2.0
Adipocytes (cell),LOCATION_OF,Calcium (bacs),PART_OF,Cytosol (celc),4.44e-09,108.31,5,23,0,6.09,2.0
Adipocytes (cell),LOCATION_OF,Calcium (bacs),PREDISPOSES,Atherosclerosis (dsyn),5.64e-07,113.75,5,12,0,7.08,2.0
Adipocytes (cell),LOCATION_OF,Calcium (bacs),PART_OF,Extracellular (celc),4.44e-09,108.25,5,19,0,6.32,2.0
Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),2.74e-06,11.53,11,11,0,22.0,6.0
Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),2.44e-06,9.07,11,21,0,16.76,6.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,Cardiovascular Diseases (dsyn),5.12e-06,10.89,11,10,0,19.09,4.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,"Hyperparathyroidism, Secondary (dsyn)",2.45e-06,8.61,11,18,0,17.72,4.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,Critical Illness (dsyn),2.53e-06,12.71,11,11,0,22.0,4.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,"Kidney Failure, Chronic (dsyn)",2.44e-06,8.73,11,24,0,16.04,4.0
Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",2.44e-06,8.66,11,28,0,15.32,6.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (popg),3.8e-10,33.66,8,33,0,9.94,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,34.2,8,16,0,12.0,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.21e-10,34.01,8,71,0,8.9,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.21e-10,47.85,8,35,0,9.83,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.21e-10,33.93,8,110,0,8.58,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),1.48e-09,33.27,8,37,0,9.73,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),5.86e-06,31.55,5,9,0,7.78,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),3.27e-06,30.61,5,194,0,5.13,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.27e-06,29.33,5,17,0,6.47,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.27e-06,30.6,5,29,0,5.86,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),3.27e-06,32.78,5,14,0,6.79,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),4.33e-06,28.59,5,12,0,7.08,5.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.27e-06,27.41,5,48,0,5.52,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),3.27e-06,30.8,5,29,0,5.86,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.27e-06,27.85,5,98,0,5.26,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),3.27e-06,26.51,5,24,0,6.04,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),3.44e-06,32.92,5,10,0,7.5,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),3.28e-06,25.28,5,37,0,5.68,7.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.27e-06,27.08,5,20,0,6.25,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (popg),3.27e-06,28.74,5,94,0,5.27,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),5.61e-06,34.53,5,8,0,8.12,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (popg),3.27e-06,31.4,5,19,0,6.32,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),3.27e-06,28.56,5,21,0,6.19,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),3.27e-06,33.74,5,12,0,7.08,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.27e-06,41.45,5,10,0,7.5,21.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),3.35e-06,34.04,5,10,0,7.5,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),3.27e-06,28.36,5,21,0,6.19,21.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.27e-06,29.97,5,21,0,6.19,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.27e-06,28.09,5,32,0,5.78,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.3e-06,35.45,5,10,0,7.5,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.27e-06,34.42,5,39,0,5.64,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.27e-06,38.4,5,44,0,5.57,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.27e-06,31.27,5,113,0,5.22,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),6.02e-06,28.8,5,11,0,7.27,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),7.44e-06,28.53,5,11,0,7.27,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),3.83e-06,28.99,5,12,0,7.08,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),3.27e-06,26.88,5,25,0,6.0,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (humn)",3.27e-06,32.56,5,87,0,5.29,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.27e-06,27.54,5,33,0,5.76,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (popg),3.27e-06,30.28,5,41,0,5.61,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),3.27e-06,30.45,5,21,0,6.19,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",3.27e-06,28.11,5,21,0,6.19,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.27e-06,29.06,5,1021,0,5.02,11.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),USES,Medicare (rnlw),9.97e-10,24.48,12,20,0,19.2,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,21.67,12,65,0,14.22,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),USES,Treats (clas),3.75e-07,23.99,12,16,0,21.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Calcium (bacs),4.09e-06,24.25,12,13,0,23.08,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),USES,Classification (clas),1.22e-08,25.23,12,16,0,21.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Sodium (elii),3.47e-06,30.63,12,8,0,13.33,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,C-reactive protein (aapp),1.77e-10,24.11,12,23,0,18.26,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,25.01,12,22,0,18.55,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),8.85e-07,24.93,12,13,0,23.08,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,26.93,12,15,0,21.6,1.0
Adipose tissue (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,47.66,10,16,0,16.25,7.0
Adipose tissue (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,52.83,10,9,0,17.1,7.0
Adipose tissue (tisu),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,45.21,10,31,0,13.23,7.0
Adipose tissue (tisu),LOCATION_OF,Polymerase Chain Reaction (lbpr),DIAGNOSES,Primary Neoplasm (neop),4.1e-06,82.56,5,12,0,7.08,2.0
Adipose tissue (tisu),LOCATION_OF,Polymerase Chain Reaction (lbpr),USES,Immunohistochemistry (lbpr),2.95e-07,80.82,5,21,0,6.19,2.0
Adipose tissue (tisu),LOCATION_OF,Polymerase Chain Reaction (lbpr),DIAGNOSES,Virus Diseases (dsyn),3.04e-06,79.96,5,27,0,5.93,2.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.25e-07,41.33,5,25,0,6.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.25e-07,45.23,5,15,0,6.67,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),4.25e-07,50.61,5,24,0,6.04,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),4.25e-07,41.24,5,46,0,5.54,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PROCESS_OF,General Population (popg),4.25e-07,40.81,5,24,0,6.04,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),4.25e-07,42.66,5,18,0,6.39,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),4.25e-07,39.39,5,73,0,5.34,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),5.19e-07,39.98,5,24,0,6.04,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",4.25e-07,41.3,5,41,0,5.61,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),4.26e-07,42.08,5,19,0,6.32,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.25e-07,42.96,5,26,0,5.96,8.0
Leptin|LEP (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.82e-06,65.2,4,16,0,5.0,9.0
Leptin|LEP (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),2.72e-06,70.36,4,9,0,5.78,9.0
Leptin|LEP (aapp),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.89e-06,62.75,4,31,0,4.52,21.0
